손보 3사 + 도쿄해상 — 배당은 국채를 이기는가, 매출·이익은 자라는가, 돈은 어디에 묶여 있는가Three Korean P&C insurers + Tokio Marine — do dividends beat government bonds, are revenue and profit growing, and where is the money tied up?韓国損保3社 + Tokio Marine — 配当は国債に勝つか、売上・利益は伸びているか、資金はどこに縛られているか
삼성화재·현대해상·DB손해보험의 DART 정기보고서(2019Q1~, 원문 표·주석 포함)와 도쿄해상홀딩스의 EDINET 有価証券報告書·四半期·半期報告書(FY2018~FY2025, 재무제표와 주석)를 Raw Data 로 삼아 배당·이익수익률을 KTB/JGB/UST 10Y 옆에 놓고, 보험료·보험수익·순이익의 성장, 지분 구조(최대주주·상호보유·Berkshire), 유가증권·운용자산 포트폴리오, 정책보유주식이 이익으로 바뀌는 경로, 지급여력·솔벤시·ESR 을 같은 틀로 편다. 숫자 표가 '-' 인 자리는 원문 문장을 그대로 옮겼다.Using as Raw Data the DART periodic reports of Samsung F&M, Hyundai M&F and DB Insurance (from 2019Q1, including original tables and notes) and Tokio Marine's EDINET annual, quarterly and half-year securities reports (FY2018–FY2025, financial statements and notes), this page sets dividend and earnings yields next to the KTB/JGB/UST 10Y and lays out, in one frame, the growth of premiums, insurance revenue and net income; ownership (largest shareholders, cross-shareholdings, Berkshire); securities and invested-asset portfolios; the path by which policy shareholdings turn into profit; and solvency (K-ICS, solvency margin, ESR). Where a numeric table shows '-', the original sentence is quoted as is.Samsung F&M・Hyundai M&F・DB InsuranceのDART定期報告書(2019Q1〜、原文の表・注記を含む)とTokio MarineのEDINET有価証券報告書・四半期報告書・半期報告書(FY2018〜FY2025、財務諸表と注記)をRaw Dataとし、配当利回り・益回りをKTB/JGB/UST 10年と並べ、保険料・保険収益・純利益の成長、株主構成(筆頭株主・相互保有・Berkshire)、有価証券・運用資産ポートフォリオ、政策保有株式が利益に変わる経路、支払余力・ソルベンシー・ESRを同じ枠組みで示す。数値の表が「-」の箇所は原文をそのまま引いた。
먼저 보는 세 줄 · 2026-08-14Three lines first · 2026-08-14まず見る三行 · 2026-08-14
배당 vs 국채 삼성화재 FY2025 3.9% vs KTB 3.38% · 현대해상 FY2023 5.8% vs KTB 3.18% · DB손보 FY2025 5.4% vs KTB 3.38% — 현대해상은 FY2024·FY2025 결산배당 미실시(원문: 법정적립금으로 배당가능이익 소진).Dividends vs. government bonds Samsung F&M FY2025 3.9% vs KTB 3.38% · Hyundai M&F FY2023 5.8% vs KTB 3.18% · DB Insurance FY2025 5.4% vs KTB 3.38% — Hyundai M&F skipped the year-end dividend for FY2024·FY2025 (company's wording: distributable profit exhausted by statutory reserves).配当 vs 国債 Samsung F&M FY2025 3.9% vs KTB 3.38% · Hyundai M&F FY2023 5.8% vs KTB 3.18% · DB Insurance FY2025 5.4% vs KTB 3.38% — Hyundai M&FはFY2024·FY2025の期末配当を見送った(原文:法定積立金で配当可能利益が消失)。
도쿄해상: FY2025 배당수익률 2.98% vs JGB10Y 2.37% · UST10Y 4.30%.Tokio Marine: FY2025 dividend yield 2.98% vs JGB10Y 2.37% · UST10Y 4.30%.Tokio Marine:FY2025 配当利回り2.98% vs JGB10Y 2.37% · UST10Y 4.30%。
자본 K-ICS 삼성화재 282.8% · 현대해상 209.0% · DB손보 204.4% · 도쿄해상 ESR 268% (99.5% VaR 새 정의 · 목표 ≥190%) — 체계가 달라 수준을 나란히 비교하지 않는다.Capital K-ICS Samsung F&M 282.8% · Hyundai M&F 209.0% · DB Insurance 204.4% · Tokio Marine ESR 268% (99.5% VaR, new definition · target ≥190%) — different regimes, so the levels are not compared side by side.資本 K-ICS Samsung F&M 282.8% · Hyundai M&F 209.0% · DB Insurance 204.4% · Tokio Marine ESR 268%(99.5% VaR・新定義 · 目標≥190%) — 制度が異なるため水準を並べて比較しない。
삼성화재 DY FY2025Samsung F&M DY FY2025Samsung F&M DY FY2025
3.9%
KTB10Y 3.38% · EY 9.5%
현대해상 DY FY2023Hyundai M&F DY FY2023Hyundai M&F DY FY2023
5.8%
KTB10Y 3.18% · EY 20.2%
DB손보 DY FY2025DB Insurance DY FY2025DB Insurance DY FY2025
2029년도 말 0 목표 · 상호보유 50종목target: zero by end-FY2029 · 50 cross-held names2029年度末にゼロ目標 · 相互保有50銘柄
ESR 2026-03
268%
99.5% VaR 새 정의 · 목표 ≥190%99.5% VaR, new definition · target ≥190%99.5% VaR・新定義 · 目標≥190%
회계연도(FY)는 회사 결산 기준 — 한국 3사는 12월, 도쿄해상은 3월(FY2025 = 2025-04~2026-03). 같은 기간이 여러 보고서에 실리면 최신 제출분을 쓰고 최초 값은 Raw Data 에 남긴다. 주가는 시세 Raw Data 가 아니다: 한국 = 회사 기재 배당수익률과 DPS 로 역산(배당 없는 해는 없음), 도쿄해상 = 有報의 EPS×PER 역산(3월말). 금액은 원·엔이 섞이므로 회사 간 비교는 비율로만 한다.Fiscal years (FY) follow each company's year-end — December for the three Korean insurers, March for Tokio Marine (FY2025 = 2025-04 to 2026-03). When the same period appears in several reports, the most recent filing is used and the first-reported value is kept in the Raw Data. Share prices are not market-price Raw Data: Korea = backed out from the company-reported dividend yield and DPS (none for years without a dividend); Tokio Marine = backed out from EPS × PER in the annual securities report (March-end). Amounts mix won and yen, so companies are compared only through ratios.会計年度(FY)は各社の決算期 — 韓国3社は12月、Tokio Marineは3月(FY2025 = 2025年4月〜2026年3月)。同じ期間が複数の報告書に載る場合は最新の提出分を使い、当初の値はRaw Dataに残す。株価は株価のRaw Dataではない:韓国 = 会社開示の配当利回りとDPSから逆算(配当のない年はなし)、Tokio Marine = 有報のEPS×PERから逆算(3月末)。金額はウォンと円が混在するため、会社間の比較は比率でのみ行う。
Observation: Samsung F&M FY2025 dividend yield 3.9% vs KTB10Y 3.38% (earnings yield 9.5%) · Hyundai M&F FY2023 dividend yield 5.8% vs KTB10Y 3.18% (earnings yield 20.2%) · DB Insurance FY2025 dividend yield 5.4% vs KTB10Y 3.38% (earnings yield 21.0%). Hyundai M&F paid no dividend for FY2024·25 (company's wording: distributable profit exhausted by the increase in statutory reserves). Solvency ratio (K-ICS) Samsung F&M 282.8% · Hyundai M&F 209.0% · DB Insurance 204.4%. Tokio Marine: FY2025 dividend yield 2.98% vs JGB10Y 2.37% · UST10Y 4.30%. Earnings yield J-GAAP 7.1% / IFRS 3.8% — the gap is because gains on selling policy stocks (FY2025 disposal gain JPY 0.66trn) bypass profit and loss under IFRS. Listed policy holdings JPY 1.92trn → target zero by end-FY2029; cross-holdings 101 → 50 names. 2.5% allotted to Berkshire (NICO).
観測:Samsung F&M FY2025 配当利回り3.9% vs KTB10Y 3.38%(益回り9.5%) · Hyundai M&F FY2023 配当利回り5.8% vs KTB10Y 3.18%(益回り20.2%) · DB Insurance FY2025 配当利回り5.4% vs KTB10Y 3.38%(益回り21.0%)。Hyundai M&FはFY2024・25が無配(原文:法定積立金の増加で配当可能利益が消失)。支払余力比率(K-ICS)Samsung F&M 282.8% · Hyundai M&F 209.0% · DB Insurance 204.4%。Tokio Marine:FY2025 配当利回り2.98% vs JGB10Y 2.37% · UST10Y 4.30%。益回りは日本基準7.1% / IFRS 3.8% — 差は政策株式の売却益(FY2025の処分益0.66兆円)がIFRSでは損益を通らないため。上場の政策保有1.92兆円 → 2029年度末にゼロ目標、相互保有101→50銘柄。Berkshire(NICO)に2.5%を割当。
01
한 표 — 배당·이익수익률을 국채 10Y 옆에One table — dividend and earnings yields next to the 10Y government bond一覧表 — 配当利回り・益回りを10年国債と並べる
한 표One table一覧表Three insurers: dividend yield and earnings yield next to KTB/UST 10Y (company fiscal year-end)Three insurers: dividend yield and earnings yield next to KTB/UST 10Y (company fiscal year-end)3社:配当利回りと益回りをKTB/UST 10年と並べる(各社の決算期末)
회사
FY
DPS(원)
배당수익률
KTB10Y(연말)
UST10Y
배당−KTB
EPS(연결)
이익수익률*
이익수익률−KTB
배당성향
순이익
K-ICS
삼성화재
FY2025
19,500
3.9%
3.38%
4.18%
+0.52%p
47,478
9.5%
+6.11%p
41.1%
2.02조
262.9%
현대해상
FY2023
2,063
5.8%
3.18%
3.88%
+2.62%p
7,185
20.2%
+17.02%p
28.2%
0.57조
173.2%
DB손보
FY2025
7,600
5.4%
3.38%
4.18%
+2.02%p
29,597
21.0%
+17.64%p
25.7%
1.79조
217.8%
Company
FY
DPS (KRW)
Dividend yield
KTB10Y (year-end)
UST10Y
DY − KTB
EPS (consol.)
Earnings yield*
EY − KTB
Payout ratio
Net income
K-ICS
Samsung F&M
FY2025
19,500
3.9%
3.38%
4.18%
+0.52pp
47,478
9.5%
+6.11pp
41.1%
KRW 2.02trn
262.9%
Hyundai M&F
FY2023
2,063
5.8%
3.18%
3.88%
+2.62pp
7,185
20.2%
+17.02pp
28.2%
KRW 0.57trn
173.2%
DB Insurance
FY2025
7,600
5.4%
3.38%
4.18%
+2.02pp
29,597
21.0%
+17.64pp
25.7%
KRW 1.79trn
217.8%
会社
FY
DPS(ウォン)
配当利回り
KTB10Y(年末)
UST10Y
配当−KTB
EPS(連結)
益回り*
益回り−KTB
配当性向
純利益
K-ICS
Samsung F&M
FY2025
19,500
3.9%
3.38%
4.18%
+0.52pt
47,478
9.5%
+6.11pt
41.1%
2.02兆ウォン
262.9%
Hyundai M&F
FY2023
2,063
5.8%
3.18%
3.88%
+2.62pt
7,185
20.2%
+17.02pt
28.2%
0.57兆ウォン
173.2%
DB Insurance
FY2025
7,600
5.4%
3.38%
4.18%
+2.02pt
29,597
21.0%
+17.64pt
25.7%
1.79兆ウォン
217.8%
배당수익률은 DART '배당에 관한 사항'의 회사 기재값(배당기준일 전 1주일 평균 종가 기준), 이익수익률*은 그 수익률과 DPS 로 역산한 주가에 연결 EPS 를 나눈 값(시세 Raw Data 없이 같은 날짜 기준). 국채는 레포의 3국 커브 Raw Data(ECOS·FRED) 연말값. 현대해상 원문(FY2025 사업보고서): “배당가능이익이 소진됨에 따라 배당이 불가한 상황입니다.”
Dividend yield is the company-reported value in DART's 'matters concerning dividends' (based on the average close over the week before the record date); earnings yield* is consolidated EPS divided by the price backed out from that yield and the DPS (same date, without market-price Raw Data). Government bond yields are year-end values from the site's three-country yield-curve Raw Data (ECOS · FRED). Hyundai M&F original text (FY2025 annual report): “배당가능이익이 소진됨에 따라 배당이 불가한 상황입니다.”
⚠ 규율: 현대해상은 FY2024·FY2025 결산배당을 하지 않았다 — 표의 '미실시'. 이유는 회사 문장 그대로(법정적립금 증가로 배당가능이익 소진). FY2025 순이익 1.02조·ROE 20.6% 라도 배당은 0 — 숫자만 보면 놓친다.
⚠ Discipline: Hyundai M&F paid no year-end dividend for FY2024·FY2025 — 'not paid' in the table. The reason is the company's own wording (distributable profit exhausted by the increase in statutory reserves). Even with FY2025 net income of KRW 1.02trn and ROE of 20.6%, the dividend is zero — easy to miss from the numbers alone.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 배당수익률은 회사 기재값(기준가 = 배당기준일 전 1주일 평균 종가) · 이익수익률은 그 수익률과 DPS 로 역산한 주가 기준이라 배당 없는 해는 빈다 · 국채는 회계연도 말 값 · K-ICS 경과조치 적용은 회사마다 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Dividend yield is the company-reported value (reference price = average close over the week before the record date) · earnings yield uses the price backed out from that yield and the DPS, so years without a dividend are blank · government bond yields are fiscal year-end values · whether K-ICS transitional measures apply differs by company.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
02
배당 — 수익률·성향·국채 스프레드Dividends — yield, payout and spread over government bonds配当 — 利回り・配当性向・国債とのスプレッド
수익률Yield利回りDividend yield vs. KTB 10Y and UST 10YDividend yield vs. KTB 10Y and UST 10Y配当利回り vs KTB 10年・UST 10年
삼성화재 FY2025 3.9% · 현대해상 FY2023 5.8% · DB손보 FY2025 5.4% (배당 있는 마지막 해). 선이 끊긴 곳이 배당 미실시.
Samsung F&M FY2025 3.9% · Hyundai M&F FY2023 5.8% · DB Insurance FY2025 5.4% (last year with a dividend). Where a line breaks, no dividend was paid.
⚠ 규율: 회사 기재 수익률의 기준가는 배당기준일 전 1주일 평균 — 연말 종가와 조금 다르다.
⚠ Discipline: The reference price for the company-reported yield is the average over the week before the dividend record date — slightly different from the year-end close.
⚠ 規律:会社開示の利回りの基準株価は配当基準日前1週間の平均 — 年末終値とは少し異なる。
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 배당수익률 기준가는 배당기준일 전 1주일 평균 종가라 연말 종가와 다르다 · 선이 끊긴 곳 = 배당 미실시. Definitions: company-reported cash dividend yield (DART); sovereign = last trading day of the fiscal year.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: The reference price for the dividend yield is the average close over the week before the record date, so it differs from the year-end close · a break in a line = no dividend paid. Definitions: company-reported cash dividend yield (DART); sovereign = last trading day of the fiscal year.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 配当利回りの基準株価は配当基準日前1週間の平均終値で、年末終値とは異なる · 線が途切れた所 = 無配。 Definitions: company-reported cash dividend yield (DART); sovereign = last trading day of the fiscal year.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
스프레드SpreadスプレッドDividend yield minus KTB 10Y (percentage points)Dividend yield minus KTB 10Y (percentage points)配当利回り − KTB 10年(%ポイント)
Limitations: 배당수익률은 회사 기재값 · KTB10Y 는 회계연도 마지막 영업일 값 · 배당 미실시 해는 빈칸. Definitions: negative = the bond pays more than the stock's cash dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: Dividend yield is the company-reported value · KTB10Y is the value on the last business day of the fiscal year · years without a dividend are blank. Definitions: negative = the bond pays more than the stock's cash dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 配当利回りは会社開示値 · KTB10Yは会計年度最終営業日の値 · 無配の年は空欄。 Definitions: negative = the bond pays more than the stock's cash dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
삼성화재 FY2025 EY 9.5% (KTB 3.38%) · 현대해상 FY2023 EY 20.2% (KTB 3.18%) · DB손보 FY2025 EY 21.0% (KTB 3.38%).
Samsung F&M FY2025 EY 9.5% (KTB 3.38%) · Hyundai M&F FY2023 EY 20.2% (KTB 3.18%) · DB Insurance FY2025 EY 21.0% (KTB 3.38%).
Samsung F&M FY2025 EY 9.5%(KTB 3.38%) · Hyundai M&F FY2023 EY 20.2%(KTB 3.18%) · DB Insurance FY2025 EY 21.0%(KTB 3.38%)。
⚠ 규율: 배당이 없는 해는 주가를 역산할 수 없어 빈다(현대해상 FY2024~25).
⚠ Discipline: Years without a dividend are blank because the price cannot be backed out (Hyundai M&F FY2024–25).
⚠ 規律:配当のない年は株価を逆算できないため空欄(Hyundai M&F FY2024〜25)。
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 주가는 시세 Raw Data 가 아니라 DPS ÷ 배당수익률로 역산했다 — 배당 없는 해는 계산하지 못한다 · EPS 는 연결. Definitions: EPS ÷ (DPS ÷ reported dividend yield); needs a dividend to back out the price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: The price is not taken from market-price Raw Data; it is backed out as DPS ÷ dividend yield — it cannot be computed for years without a dividend · EPS is consolidated. Definitions: EPS ÷ (DPS ÷ reported dividend yield); needs a dividend to back out the price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 株価は株価のRaw Dataではなく、DPS ÷ 配当利回りで逆算した — 配当のない年は計算できない · EPSは連結。 Definitions: EPS ÷ (DPS ÷ reported dividend yield); needs a dividend to back out the price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
배당Dividend配当Dividend per share and payout ratioDividend per share and payout ratio1株当たり配当と配当性向
회사
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
삼성화재
45.8%
56.2%
49.6%
45.5%
45.8%
37.4%
39.0%
41.1%
현대해상
24.1%
26.1%
23.9%
26.8%
26.8%
28.2%
n/a
n/a
DB손보
23.8%
25.4%
23.9%
24.2%
28.1%
18.3%
22.0%
25.7%
연결 현금배당성향(%) — DART 기재값.
Company
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Samsung F&M
45.8%
56.2%
49.6%
45.5%
45.8%
37.4%
39.0%
41.1%
Hyundai M&F
24.1%
26.1%
23.9%
26.8%
26.8%
28.2%
n/a
n/a
DB Insurance
23.8%
25.4%
23.9%
24.2%
28.1%
18.3%
22.0%
25.7%
Consolidated cash payout ratio (%) — as reported to DART.
Limitations: 보통주 DPS · 배당성향은 연결 기준 회사 기재값 · 최신 사업보고서가 이전 연도를 덮는다(정정 반영). Definitions: common shares; blank = no dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Common-share DPS · the payout ratio is the company-reported consolidated value · the latest annual report overrides earlier years (corrections reflected). Definitions: common shares; blank = no dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 普通株のDPS · 配当性向は連結ベースの会社開示値 · 最新の事業報告書が過去の年度を上書きする(訂正を反映)。 Definitions: common shares; blank = no dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
여력Capacity配当余力Retained earnings vs. statutory reserves (surrender-value, catastrophe, credit-loss)Retained earnings vs. statutory reserves (surrender-value, catastrophe, credit-loss)利益剰余金 vs 法定積立金(解約返戻金・異常危険・貸倒)
삼성화재 FY2025: 이익잉여금 14.64조 vs 법정적립금 6.96조 (해약환급금준비금 4.13조) · 현대해상 FY2025: 이익잉여금 8.16조 vs 법정적립금 5.34조 (해약환급금준비금 3.92조) · DB손보 FY2025: 이익잉여금 13.31조 vs 법정적립금 8.41조 (해약환급금준비금 6.55조).
Samsung F&M FY2025:利益剰余金14.64兆ウォン vs 法定積立金6.96兆ウォン(解約返戻金準備金4.13兆ウォン) · Hyundai M&F FY2025:利益剰余金8.16兆ウォン vs 法定積立金5.34兆ウォン(解約返戻金準備金3.92兆ウォン) · DB Insurance FY2025:利益剰余金13.31兆ウォン vs 法定積立金8.41兆ウォン(解約返戻金準備金6.55兆ウォン)。
⚠ 규율: 상법 배당가능이익은 **별도** 기준이고 여기 값은 연결 재무상태표 주기(기적립+적립예정)라 근사치다. 현대해상이 '배당 불가' 라고 적은 메커니즘이 이 열이다.
⚠ Discipline: Distributable profit under the Commercial Act is on a **separate** basis, and the values here come from the notes to the consolidated balance sheet (already reserved + to be reserved), so they are approximations. This column is the mechanism Hyundai M&F described when it wrote 'no dividend possible'.
Limitations: 연결 재무상태표 주기(기적립 + 적립예정)라 상법 배당가능이익(별도 기준)과 다르다 — 근사치. Definitions: latest fiscal year; reserves are carved out of retained earnings before dividends can be paid.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Taken from the notes to the consolidated balance sheet (already reserved + to be reserved), so it differs from distributable profit under the Commercial Act (separate basis) — an approximation. Definitions: latest fiscal year; reserves are carved out of retained earnings before dividends can be paid.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 連結貸借対照表の注記(積立済み + 積立予定)のため、商法上の配当可能利益(単体基準)とは異なる — 近似値。 Definitions: latest fiscal year; reserves are carved out of retained earnings before dividends can be paid.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
03
성장 — 수입보험료·보험수익과 순이익Growth — premium income, insurance revenue and net income成長 — 収入保険料・保険収益と純利益
매출Top line売上Premium income by fiscal year (regulatory basis, spans IFRS 4 → 17)Premium income by fiscal year (regulatory basis, spans IFRS 4 → 17)年度別収入保険料(監督基準、IFRS 4→17をまたぐ)
⚠ 규율: 회사마다 표의 정의가 다르다(삼성화재 FY2023 부터 퇴직연금 포함 보험료수익으로 점프). 원문에 종속회사 표만 남아 비운 해: 삼성화재 FY2022 0.29조. 시대를 넘는 성장률은 같은 회사 안에서만.
⚠ Discipline: Table definitions differ by company (Samsung F&M jumps from FY2023 to premium revenue including retirement pensions). Years blanked because only a subsidiary's table remained in the filing: Samsung F&M FY2022 KRW 0.29trn. Growth across the two accounting eras only within the same company.
Limitations: 회사마다 표의 정의가 다르다(삼성화재 FY2023 부터 퇴직연금 포함) · 본사 표 없이 종속회사 표만 남은 해는 비웠다 · 회계기준을 건너는 업무보고서 기준. Definitions: Samsung = premium revenue incl. retirement pensions; Hyundai, DB = gross premiums written (DB table dropped from FY2024).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Table definitions differ by company (Samsung F&M includes retirement pensions from FY2023) · years where only a subsidiary's table remained, without the parent's, are left blank · business-report basis, which spans the change of accounting standard. Definitions: Samsung = premium revenue incl. retirement pensions; Hyundai, DB = gross premiums written (DB table dropped from FY2024).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 表の定義は会社ごとに異なる(Samsung F&MはFY2023から退職年金を含む)· 親会社の表がなく子会社の表だけが残った年は空欄 · 会計基準の変更をまたぐ業務報告書ベース。 Definitions: Samsung = premium revenue incl. retirement pensions; Hyundai, DB = gross premiums written (DB table dropped from FY2024).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
IFRS 17Insurance revenue and insurance service result (IFRS 17, FY2022 restated onward)Insurance revenue and insurance service result (IFRS 17, FY2022 restated onward)保険収益と保険サービス損益(IFRS 17、FY2022再表示以降)
⚠ Discipline: Insurance result = insurance operating revenue − insurance operating expenses (incl. other business expenses). The investment result is separate.
⚠ 規律:保険損益 = 保険営業収益 − 保険営業費用(その他事業費用を含む)。投資損益は別。
Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 연결 · FY2022 는 FY2023 보고서의 재작성 비교값 · 보험손익 = 보험영업수익 − 보험영업비용(투자손익 제외). Definitions: consolidated; FY2022 is the restated comparative in the FY2023 report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 consolidated · FY2022 is the restated comparative in the FY2023 report · insurance result = insurance operating revenue − insurance operating expenses (excl. investment result). Definitions: consolidated; FY2022 is the restated comparative in the FY2023 report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: IFRS 17連結 · FY2022はFY2023報告書の再表示比較値 · 保険損益 = 保険営業収益 − 保険営業費用(投資損益を除く)。 Definitions: consolidated; FY2022 is the restated comparative in the FY2023 report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
이익Earnings利益Consolidated net income by fiscal year (from the dividend table — spans both regimes)Consolidated net income by fiscal year (from the dividend table — spans both regimes)年度別の連結純利益(配当表から — 両会計基準をまたぐ)
⚠ 규율: FY2022→FY2023 은 회계기준이 바뀐다 — 그 한 칸의 증감은 성장이 아니다.
⚠ Discipline: The accounting standard changes between FY2022 and FY2023 — the change across that one step is not growth.
⚠ 規律:FY2022→FY2023は会計基準が変わる — その1区間の増減は成長ではない。
Source: DART, Financial Supervisory Service.
Limitations: 배당표의 연결 순이익 — FY2022 까지 IFRS 4(최초 공시), FY2023 부터 IFRS 17 이라 한 계열이 아니다. Definitions: IFRS 4 through FY2022 as originally reported, IFRS 17 from FY2023; not one series.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Consolidated net income from the dividend table — IFRS 4 (as first reported) through FY2022 and IFRS 17 from FY2023, so it is not one series. Definitions: IFRS 4 through FY2022 as originally reported, IFRS 17 from FY2023; not one series.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: 配当表の連結純利益 — FY2022まではIFRS 4(当初開示)、FY2023からはIFRS 17のため一つの系列ではない。 Definitions: IFRS 4 through FY2022 as originally reported, IFRS 17 from FY2023; not one series.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
04
지분 구조 — 최대주주·특수관계인·자기주식Ownership — largest shareholder, related parties, treasury shares株主構成 — 筆頭株主・特別関係者・自己株式
지분Ownership持分Samsung F&M: largest-shareholder group and treasury sharesSamsung F&M: largest-shareholder group and treasury sharesSamsung F&M:筆頭株主グループと自己株式
주주
관계
기초 지분
기말 지분
기말 주식수
삼성생명
최대주주 본인
15.43%
15.90%
7,099,088
삼성문화재단
최대주주의 계열 비영리법인
3.15%
3.25%
1,451,241
삼성복지재단
최대주주의 계열 비영리법인
0.37%
0.38%
170,517
이재용
최대주주의 특수관계인
0.10%
0.10%
44,000
이문화
최대주주의 계열회사 등기임원
0.00%
0.00%
300
박진회
최대주주의 계열회사 등기임원
0.00%
0.00%
50
Holder
Relation
Stake, start
Stake, end
Shares, end
삼성생명
largest shareholder
15.43%
15.90%
7,099,088
삼성문화재단
non-profit affiliate of the largest shareholder
3.15%
3.25%
1,451,241
삼성복지재단
non-profit affiliate of the largest shareholder
0.37%
0.38%
170,517
이재용
related party of the largest shareholder
0.10%
0.10%
44,000
이문화
registered executive of an affiliate of the largest shareholder
0.00%
0.00%
300
박진회
registered executive of an affiliate of the largest shareholder
Latest (2026H1): 삼성생명 (largest shareholder) 15.9% · 삼성문화재단 (non-profit affiliate of the largest shareholder) 3.25% · 삼성복지재단 (non-profit affiliate of the largest shareholder) 0.38%. Treasury shares 4,819,177 / total shares issued 44,647,473 (10.8%, as of 2026H1).
⚠ Discipline: Changes in the largest shareholder: none recorded.
⚠ 規律:筆頭株主の異動:記録なし。
Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 자기주식 비율 분모 = 발행주식 총수(소각 뒤) · 개인 지배주주의 간접 지분은 이 표에 없다. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · treasury-share ratio denominator = total shares issued (after cancellation) · indirect stakes of individual controlling shareholders are not in this table. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분Ownership持分Hyundai M&F: largest-shareholder group and treasury sharesHyundai M&F: largest-shareholder group and treasury sharesHyundai M&F:筆頭株主グループと自己株式
Latest (2026H1): 정몽윤 (largest shareholder) 23.08% · 정경선 (child of the largest shareholder) 0.48% · 정정이 (child of the largest shareholder) 0.4%. Treasury shares 5,939,750 / total shares issued 85,248,250 (7.0%, as of 2026H1).
Limitations: DART 최대주주 현황(보통주) · 자기주식 비율 분모 = 발행주식 총수(소각 뒤) · 개인 지배주주의 간접 지분은 이 표에 없다. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · treasury-share ratio denominator = total shares issued (after cancellation) · indirect stakes of individual controlling shareholders are not in this table. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분Ownership持分DB Insurance: largest-shareholder group and treasury sharesDB Insurance: largest-shareholder group and treasury sharesDB Insurance:筆頭株主グループと自己株式
Limitations: DART 최대주주 현황(보통주) · 자기주식 비율 분모 = 발행주식 총수(소각 뒤) · 개인 지배주주의 간접 지분은 이 표에 없다. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · treasury-share ratio denominator = total shares issued (after cancellation) · indirect stakes of individual controlling shareholders are not in this table. Definitions: DART largest-shareholder table; x = fiscal quarter.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
출자Stakes出資DB Insurance: investments in other companies (largest by book value)DB Insurance: investments in other companies (largest by book value)DB Insurance:他法人への出資(簿価上位)
⚠ 규율: 삼성화재·현대해상은 이 표를 '-' 로 비웠다 — 출자 내역은 주석(관계기업·지분증권)에서 따로 읽어야 한다(다음 단계).
⚠ Discipline: Samsung F&M and Hyundai M&F left this table blank ('-') — the investment details have to be read separately from the notes (associates, equity securities) (a later step).
Limitations: DART 타법인출자 현황 — 삼성화재·현대해상은 이 표를 비웠다(주석에서 따로 읽어야 함).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: DART table of investments in other companies — Samsung F&M and Hyundai M&F left this table empty (it has to be read from the notes).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
05
채권·운용자산 포트폴리오 — 유가증권 운용내역(업무보고서 기준)Bond and invested-asset portfolio — securities by type (business-report basis)債券・運用資産ポートフォリオ — 有価証券の運用内訳(業務報告書ベース)
⚠ 규율: 외화유가증권은 채권·주식이 섞인 회사 정의(현대해상은 해외 주식·출자금·펀드 제외). 신용등급·잔존만기는 주석 표에서 다음 단계.
⚠ Discipline: Foreign-currency securities follow each company's own definition and mix bonds and stocks (Hyundai M&F excludes overseas stocks, contributions and funds). Credit ratings and residual maturities come from the note tables in a later step.
Limitations: 업무보고서 기준 유가증권 운용내역 · 외화유가증권 정의는 회사마다 다르다 · 마지막 열은 최신 분기보고서. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Securities portfolio on the business-report basis · the definition of foreign-currency securities differs by company · the last column is the latest quarterly report. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
⚠ 규율: 외화유가증권은 채권·주식이 섞인 회사 정의(현대해상은 해외 주식·출자금·펀드 제외). 신용등급·잔존만기는 주석 표에서 다음 단계.
⚠ Discipline: Foreign-currency securities follow each company's own definition and mix bonds and stocks (Hyundai M&F excludes overseas stocks, contributions and funds). Credit ratings and residual maturities come from the note tables in a later step.
Limitations: 업무보고서 기준 유가증권 운용내역 · 외화유가증권 정의는 회사마다 다르다 · 마지막 열은 최신 분기보고서. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Securities portfolio on the business-report basis · the definition of foreign-currency securities differs by company · the last column is the latest quarterly report. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
DB손보 26H1: 유가증권 39.31조 중 국내채권(국공채+특수채+금융채+회사채) 14.25조 (36.2%), 외화유가증권 8.96조 (22.8%), 주식 3.99조 (10.1%), 수익증권 10.64조 (27.1%).
DB Insurance 26H1: of securities KRW 39.31trn, domestic bonds (govt & municipal + special + financial + corporate) KRW 14.25trn (36.2%), foreign-currency securities KRW 8.96trn (22.8%), stocks KRW 3.99trn (10.1%), funds (beneficiary certificates) KRW 10.64trn (27.1%).
DB Insurance 26H1:有価証券39.31兆ウォンのうち国内債券(国公債+特殊債+金融債+社債)14.25兆ウォン(36.2%)、外貨建有価証券8.96兆ウォン(22.8%)、株式3.99兆ウォン(10.1%)、受益証券10.64兆ウォン(27.1%)。
⚠ 규율: 외화유가증권은 채권·주식이 섞인 회사 정의(현대해상은 해외 주식·출자금·펀드 제외). 신용등급·잔존만기는 주석 표에서 다음 단계.
⚠ Discipline: Foreign-currency securities follow each company's own definition and mix bonds and stocks (Hyundai M&F excludes overseas stocks, contributions and funds). Credit ratings and residual maturities come from the note tables in a later step.
Limitations: 업무보고서 기준 유가증권 운용내역 · 외화유가증권 정의는 회사마다 다르다 · 마지막 열은 최신 분기보고서. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Securities portfolio on the business-report basis · the definition of foreign-currency securities differs by company · the last column is the latest quarterly report. Definitions: securities portfolio table (regulatory basis); latest column = most recent quarterly report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
운용자산Invested assets運用資産Invested assets: loans / securities / cash and their income (latest report)Invested assets: loans / securities / cash and their income (latest report)運用資産:貸付金・有価証券・現預金とその収益(最新の報告書)
⚠ 규율: '수익률' 열은 운용수익 ÷ 기말잔액(분기 보고서는 연환산 전 값) — 회사 기재 비율과 정의가 다르다.
⚠ Discipline: The 'Income / balance' column is investment income ÷ year-end balance (not annualised in quarterly reports) — defined differently from the company-reported ratio.
Limitations: 운용수익 ÷ 기말잔액(분기 보고서는 연환산 전) — 회사 기재 비율과 정의가 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Investment income ÷ year-end balance (not annualised in quarterly reports) — the definition differs from the company-reported ratio.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
06
사업 구조 — 합산비율·지급여력·CSMBusiness structure — combined ratio, solvency, CSM事業構造 — コンバインド・レシオ・支払余力・CSM
합산비율Combined ratioコンバインド・レシオLoss ratio + expense ratio = combined ratio (IFRS 4 era, company-level summary tables)Loss ratio + expense ratio = combined ratio (IFRS 4 era, company-level summary tables)損害率 + 事業費率 = コンバインド・レシオ(IFRS 4時代、会社単位の要約表)
IFRS 17 로 넘어간 FY2023 부터는 이 표가 사라진다 — 대신 보험손익/보험수익(마진)으로 본다: 삼성화재 FY2025 8.0% · 현대해상 FY2025 5.7% · DB손보 FY2025 7.0%.
From FY2023, after the move to IFRS 17, this table disappears — the insurance result / insurance revenue (margin) is used instead: Samsung F&M FY2025 8.0% · Hyundai M&F FY2025 5.7% · DB Insurance FY2025 7.0%.
⚠ Discipline: For Hyundai M&F, the total loss ratio + expense ratio from the by-line tables instead of the company summary table.
⚠ 規律:Hyundai M&Fは会社の要約表の代わりに種目別表の合計損害率 + 事業費率。
Source: DART, Financial Supervisory Service.
Limitations: IFRS 4 시대(FY2022 까지) 업무보고서 요약표 · 현대해상은 종목별 표의 합계 손해율 + 사업비율 · FY2023 부터 이 표가 없다. Definitions: loss ratio + net expense ratio; regulatory business-report basis; >100 = underwriting loss before investment income.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: Business-report summary tables from the IFRS 4 era (through FY2022) · for Hyundai M&F, total loss ratio + expense ratio from the by-line tables · this table no longer exists from FY2023. Definitions: loss ratio + net expense ratio; regulatory business-report basis; >100 = underwriting loss before investment income.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: IFRS 4時代(FY2022まで)の業務報告書の要約表 · Hyundai M&Fは種目別表の合計損害率 + 事業費率 · FY2023からこの表はない。 Definitions: loss ratio + net expense ratio; regulatory business-report basis; >100 = underwriting loss before investment income.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지급여력Solvency支払余力Solvency ratio: RBC through FY2022, K-ICS from 2023Solvency ratio: RBC through FY2022, K-ICS from 2023支払余力比率:FY2022まではRBC、2023年からK-ICS
⚠ 규율: K-ICS 경과조치 적용 여부는 회사·시점마다 다르다(원문 주석). 선이 끊긴 곳 = 그 분기 보고서에서 지급여력 표를 읽지 못한 기간(채우지 않음): 삼성화재 없음; 현대해상 19H1, 21H1; DB손보 19Q1, 23Q1.
⚠ Discipline: Whether K-ICS transitional measures apply differs by company and date (notes to the filings). A break in a line = a period whose quarterly report's solvency table could not be read (not filled): Samsung F&M none; Hyundai M&F 19H1, 21H1; DB Insurance 19Q1, 23Q1.
Limitations: RBC(~FY2022)와 K-ICS(2023~)는 체계가 달라 수준을 잇지 않는다 · 경과조치 적용은 회사·시점마다 다르다 · 표를 읽지 못한 분기는 비워 뒀다(채우지 않음). Definitions: regulatory minimum 100; the regime changes at 2023 — the two levels are not comparable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: RBC (to FY2022) and K-ICS (from 2023) are different regimes, so the levels are not joined · transitional measures differ by company and date · quarters whose table could not be read are left blank (not filled). Definitions: regulatory minimum 100; the regime changes at 2023 — the two levels are not comparable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: RBC(〜FY2022)とK-ICS(2023〜)は制度が異なるため水準をつなげない · 経過措置の適用は会社・時点ごとに異なる · 表を読めなかった四半期は空欄のまま(補完しない)。 Definitions: regulatory minimum 100; the regime changes at 2023 — the two levels are not comparable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
종목Lines種目Samsung F&M: insurance revenue and service expense by line (IFRS 17, 2026H1)Samsung F&M: insurance revenue and service expense by line (IFRS 17, 2026H1)Samsung F&M:種目別の保険収益と保険サービス費用(IFRS 17、2026H1)
longterm 5.20조 (비용 4.27조) · auto 2.74조 (비용 2.70조) · overseas 0.44조 (비용 0.21조) · 종합 0.28조 (비용 0.16조) · 책임 0.21조 (비용 0.16조) · other 0.13조 (비용 0.09조).
Limitations: IFRS 17 연결 종목별 보험수익·보험서비스비용 · 일반보험 세부 종목은 회사 분류 그대로. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 consolidated insurance revenue and insurance service expense by line · general-insurance sub-lines follow the company's own classification. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
종목Lines種目Hyundai M&F: insurance revenue and service expense by line (IFRS 17, 2026H1)Hyundai M&F: insurance revenue and service expense by line (IFRS 17, 2026H1)Hyundai M&F:種目別の保険収益と保険サービス費用(IFRS 17、2026H1)
Limitations: IFRS 17 연결 종목별 보험수익·보험서비스비용 · 일반보험 세부 종목은 회사 분류 그대로. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 consolidated insurance revenue and insurance service expense by line · general-insurance sub-lines follow the company's own classification. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
종목Lines種目DB Insurance: insurance revenue and service expense by line (IFRS 17, 2026H1)DB Insurance: insurance revenue and service expense by line (IFRS 17, 2026H1)DB Insurance:種目別の保険収益と保険サービス費用(IFRS 17、2026H1)
Limitations: IFRS 17 연결 종목별 보험수익·보험서비스비용 · 일반보험 세부 종목은 회사 분류 그대로. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: DART, Financial Supervisory Service.
Limitations: IFRS 17 consolidated insurance revenue and insurance service expense by line · general-insurance sub-lines follow the company's own classification. Definitions: IFRS 17; general-insurance sub-lines: package, liability, personal accident, engineering.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
07
도쿄해상 — 배당·이익수익률을 JGB·UST 10Y 옆에 (EDINET 有報 Raw Data)Tokio Marine — dividend and earnings yields next to JGB and UST 10Y (EDINET annual securities report Raw Data)Tokio Marine — 配当利回り・益回りをJGB・UST 10年と並べる(EDINET 有報のRaw Data)
한 표One table一覧表Tokio Marine: dividend and earnings yield next to JGB and UST 10Y (fiscal year-end, March)Tokio Marine: dividend and earnings yield next to JGB and UST 10Y (fiscal year-end, March)Tokio Marine:配当利回りと益回りをJGB・UST 10年と並べる(会計年度末、3月)
FY
DPS(분할 기준, 엔)
기말주가(역산)
배당수익률
JGB10Y
UST10Y
DY−JGB
DY−UST
EPS 일본기준
EY 일본기준
EPS IFRS
EY IFRS
배당성향(일본기준)
TSR 5년(회사 산출)
FY2018
83.3 (특별 23.3)
1,787
4.66%
-0.082%
2.41%
+4.74%p
+2.25%p
127.7
7.14%
—
—
65.3%
118
FY2019
75.0 (특별 11.7)
1,650
4.55%
0.031%
0.70%
+4.51%p
+3.85%p
123.2
7.47%
—
—
60.9%
96
FY2020
78.3 (특별 11.7)
1,755
4.46%
0.104%
1.74%
+4.36%p
+2.72%p
77.4
4.41%
—
—
101.2%
111
FY2021
85.0
2,376
3.58%
0.218%
2.32%
+3.36%p
+1.26%p
204.5
8.61%
—
—
41.6%
141
FY2022
100.0
2,546
3.93%
0.389%
3.48%
+3.54%p
+0.45%p
186.4
7.32%
—
—
53.6%
157
FY2023
123.0
4,704
2.61%
0.750%
4.20%
+1.86%p
-1.59%p
351.6
7.47%
—
—
35.0%
298
FY2024
172.0
5,736
3.00%
1.497%
4.23%
+1.50%p
-1.23%p
542.2
9.45%
231.4
4.03%
31.7%
375
FY2025
218.0
7,309
2.98%
2.366%
4.30%
+0.62%p
-1.32%p
515.5
7.05%
279.4
3.82%
42.3%
493
FY
DPS (split-adjusted, JPY)
Year-end price (implied)
Dividend yield
JGB10Y
UST10Y
DY−JGB
DY−UST
EPS J-GAAP
EY J-GAAP
EPS IFRS
EY IFRS
Payout (J-GAAP)
5-year TSR (company)
FY2018
83.3 (special 23.3)
1,787
4.66%
-0.082%
2.41%
+4.74pp
+2.25pp
127.7
7.14%
—
—
65.3%
118
FY2019
75.0 (special 11.7)
1,650
4.55%
0.031%
0.70%
+4.51pp
+3.85pp
123.2
7.47%
—
—
60.9%
96
FY2020
78.3 (special 11.7)
1,755
4.46%
0.104%
1.74%
+4.36pp
+2.72pp
77.4
4.41%
—
—
101.2%
111
FY2021
85.0
2,376
3.58%
0.218%
2.32%
+3.36pp
+1.26pp
204.5
8.61%
—
—
41.6%
141
FY2022
100.0
2,546
3.93%
0.389%
3.48%
+3.54pp
+0.45pp
186.4
7.32%
—
—
53.6%
157
FY2023
123.0
4,704
2.61%
0.750%
4.20%
+1.86pp
-1.59pp
351.6
7.47%
—
—
35.0%
298
FY2024
172.0
5,736
3.00%
1.497%
4.23%
+1.50pp
-1.23pp
542.2
9.45%
231.4
4.03%
31.7%
375
FY2025
218.0
7,309
2.98%
2.366%
4.30%
+0.62pp
-1.32pp
515.5
7.05%
279.4
3.82%
42.3%
493
FY
DPS(分割基準、円)
期末株価(逆算)
配当利回り
JGB10Y
UST10Y
DY−JGB
DY−UST
EPS 日本基準
益回り 日本基準
EPS IFRS
益回り IFRS
配当性向(日本基準)
5年TSR(会社算出)
FY2018
83.3(特別23.3)
1,787
4.66%
-0.082%
2.41%
+4.74pt
+2.25pt
127.7
7.14%
—
—
65.3%
118
FY2019
75.0(特別11.7)
1,650
4.55%
0.031%
0.70%
+4.51pt
+3.85pt
123.2
7.47%
—
—
60.9%
96
FY2020
78.3(特別11.7)
1,755
4.46%
0.104%
1.74%
+4.36pt
+2.72pt
77.4
4.41%
—
—
101.2%
111
FY2021
85.0
2,376
3.58%
0.218%
2.32%
+3.36pt
+1.26pt
204.5
8.61%
—
—
41.6%
141
FY2022
100.0
2,546
3.93%
0.389%
3.48%
+3.54pt
+0.45pt
186.4
7.32%
—
—
53.6%
157
FY2023
123.0
4,704
2.61%
0.750%
4.20%
+1.86pt
-1.59pt
351.6
7.47%
—
—
35.0%
298
FY2024
172.0
5,736
3.00%
1.497%
4.23%
+1.50pt
-1.23pt
542.2
9.45%
231.4
4.03%
31.7%
375
FY2025
218.0
7,309
2.98%
2.366%
4.30%
+0.62pt
-1.32pt
515.5
7.05%
279.4
3.82%
42.3%
493
주가는 회사가 有報에 적은 EPS × PER로 역산한 회계연도말(3월말) 주가입니다. 연결 일본기준·提出会社(지주 단체)·연결 IFRS 세 경로로 각각 계산했고 서로 1% 안에서 맞습니다(FY2025 7,309엔). DPS는 2022-10-01 1:3 분할 기준으로 맞췄습니다(원문 DPS는 분할 전 연도를 소급하지 않음 — 각주). 국채는 같은 날 10년물(재무성·FRED Raw Data).
The price is the fiscal year-end (March-end) price backed out from the EPS × PER the company reports in its annual securities report. It was calculated three ways — consolidated J-GAAP, the filing company (holding company, single entity) and consolidated IFRS — and they agree within 1% (FY2025 JPY 7,309). DPS is adjusted to the 1:3 split of 2022-10-01 (the reported DPS does not restate pre-split years — footnote). Government bonds are 10-year yields on the same day (MOF · FRED Raw Data).
⚠ 규율: FY2025 일본기준 EPS·순이익은 有報 5년 표의 '참고' 값으로 감사를 받지 않았습니다(원문 각주5). FY2022 원문 DPS 200엔은 분할 전 중간 150엔 + 분할 후 기말 50엔의 단순합 → 분할 기준 100엔. FY2018~20의 특별배당(資本水準調整のための一時的な配当)은 괄호.
⚠ Discipline: FY2025 J-GAAP EPS and net income are 'reference' values in the annual report's five-year table and are unaudited (original footnote 5). The FY2022 reported DPS of JPY 200 is a simple sum of a pre-split interim JPY 150 and a post-split year-end JPY 50 → JPY 100 on a post-split basis. The FY2018–20 special dividends (one-off dividends for capital-level adjustment) are in brackets.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 주가 = 有報의 EPS × PER 역산(3월말) · DPS 는 2022-10 주식분할 기준으로 소급(우리 계산) · FY2025 일본기준 EPS 는 미감사 참고치 · 5년 TSR 은 회사 산출(배당 재투자).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Price = backed out from EPS × PER in the annual securities report (March-end) · DPS restated to the 2022-10 share split (our calculation) · FY2025 J-GAAP EPS is an unaudited reference value · the 5-year TSR is company-calculated (dividends reinvested).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
수익률Yield利回りDividend yield and earnings yield vs. JGB 10Y and UST 10YDividend yield and earnings yield vs. JGB 10Y and UST 10Y配当利回りと益回り vs JGB 10年・UST 10年
FY2025: 배당수익률 2.98% · JGB10Y 2.37% · UST10Y 4.30% — 배당이 JGB 보다 +0.62%p 높고 UST 보다 +1.32%p 낮습니다. 이익수익률은 일본기준 7.05% vs IFRS 3.82% — 같은 해, 같은 주가인데 회계기준만 바꿔도 이익수익률이 3.2p 벌어집니다.
FY2025: dividend yield 2.98% · JGB10Y 2.37% · UST10Y 4.30% — the dividend is +0.62pp above JGBs and +1.32pp below USTs. Earnings yield J-GAAP 7.05% vs IFRS 3.82% — same year, same share price, yet switching the accounting standard alone moves the earnings yield by 3.2pp.
⚠ 규율: IFRS 선은 FY2024(비교 재작성)·FY2025 두 점뿐입니다. 일본기준 순이익에는 정책주식 매각익이 들어가고 IFRS 순이익에는 안 들어갑니다(아래 '정책보유주식' 절).
⚠ Discipline: The IFRS line has only two points, FY2024 (restated comparative) and FY2025. J-GAAP net income includes gains on selling policy stocks; IFRS net income does not (see the 'policy shareholdings' section below).
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 주가는 역산값 · IFRS 선은 FY2024(재작성)·FY2025 두 점뿐 · 국채는 3월 마지막 영업일 10년물. Definitions: price = EPS x PER from the annual report; sovereign = 10Y yield on the last business day of March.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: The price is a backed-out value · the IFRS line has only two points, FY2024 (restated) and FY2025 · government bonds are 10-year yields on the last business day of March. Definitions: price = EPS x PER from the annual report; sovereign = 10Y yield on the last business day of March.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 株価は逆算値 · IFRSの線はFY2024(再表示)とFY2025の2点のみ · 国債は3月最終営業日の10年物。 Definitions: price = EPS x PER from the annual report; sovereign = 10Y yield on the last business day of March.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
스프레드SpreadスプレッドDividend yield minus 10Y sovereign yieldDividend yield minus 10Y sovereign yield配当利回り − 10年国債利回り
⚠ 규율: JGB 10년물은 FY2018 말 −0.08%에서 FY2025 말 2.37%로 올랐습니다. 배당수익률의 JGB 대비 우위는 +4.74%p에서 +0.62%p로 줄었습니다.
⚠ Discipline: The 10-year JGB yield rose from −0.08% at end-FY2018 to 2.37% at end-FY2025. The dividend yield's lead over JGBs narrowed from +4.74pp to +0.62pp.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 주가는 역산값 · 국채는 3월 마지막 영업일 10년물. Definitions: positive = the stock's cash yield beats the bond.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: The price is a backed-out value · government bonds are 10-year yields on the last business day of March. Definitions: positive = the stock's cash yield beats the bond.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 株価は逆算値 · 国債は3月最終営業日の10年物。 Definitions: positive = the stock's cash yield beats the bond.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
4사Four insurers4社Four P&C insurers: dividend yield minus UST 10YFour P&C insurers: dividend yield minus UST 10Y損保4社:配当利回り − UST 10年
삼성화재 FY2025 -0.28%p · 현대해상 FY2023 +1.92%p · DB손보 FY2025 +1.22%p · 도쿄해상 FY2025 -1.32%p. 사용자 틀(UST 대비 배당수익률)로 보면 네 회사 모두 같은 질문에 답해야 합니다.
Samsung F&M FY2025 -0.28pp · Hyundai M&F FY2023 +1.92pp · DB Insurance FY2025 +1.22pp · Tokio Marine FY2025 -1.32pp. In the user's frame (dividend yield vs USTs), all four companies have to answer the same question.
Samsung F&M FY2025 -0.28pt · Hyundai M&F FY2023 +1.92pt · DB Insurance FY2025 +1.22pt · Tokio Marine FY2025 -1.32pt。利用者の枠組み(UST対比の配当利回り)で見ると、4社とも同じ問いに答える必要がある。
⚠ 규율: 기준일이 다릅니다: 한국 3사는 12월말(회사 기재 배당수익률, 기준가 = 배당기준일 전 1주일 평균), 도쿄해상은 3월말(DPS ÷ EPS×PER 역산 주가). 같은 FY 라벨이라도 3개월 어긋납니다. 현대해상 FY2024~25 는 배당 미실시로 빈칸.
⚠ Discipline: Reference dates differ: the three Korean insurers at end-December (company-reported dividend yield, reference price = one-week average before the record date), Tokio Marine at end-March (DPS ÷ price backed out from EPS × PER). Even with the same FY label they are three months apart. Hyundai M&F FY2024–25 are blank because no dividend was paid.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 기준일이 다르다 — 한국 3사 12월말(회사 기재 수익률), 도쿄해상 3월말(DPS ÷ 역산 주가) · 현대해상 FY2024~25 무배당은 빈칸. Definitions: Korea = December year-end, company-reported yield; Tokio Marine = March year-end, DPS ÷ implied price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Reference dates differ — the three Korean insurers at end-December (company-reported yield), Tokio Marine at end-March (DPS ÷ implied price) · Hyundai M&F's no-dividend FY2024–25 are blank. Definitions: Korea = December year-end, company-reported yield; Tokio Marine = March year-end, DPS ÷ implied price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 基準日が異なる — 韓国3社は12月末(会社開示の利回り)、Tokio Marineは3月末(DPS ÷ 逆算株価)· Hyundai M&FのFY2024〜25の無配は空欄。 Definitions: Korea = December year-end, company-reported yield; Tokio Marine = March year-end, DPS ÷ implied price.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
배당Dividend配当Dividend per share (split-adjusted): ordinary vs. one-off capital-level dividendDividend per share (split-adjusted): ordinary vs. one-off capital-level dividend1株当たり配当(分割調整後):普通配当 vs 資本水準調整の一時的な配当
분할 기준 DPS: FY18 83.3 → FY19 75.0 → FY20 78.3 → FY21 85.0 → FY22 100.0 → FY23 123.0 → FY24 172.0 → FY25 218.0. 각주의 '분할이 없었다면' DPS(분할 전 기준)는 FY2025 654엔 = 218×3 으로 검증했습니다.
Split-adjusted DPS: FY18 83.3 → FY19 75.0 → FY20 78.3 → FY21 85.0 → FY22 100.0 → FY23 123.0 → FY24 172.0 → FY25 218.0. The footnote's 'had there been no split' DPS (pre-split basis) was checked as FY2025 JPY 654 = 218 × 3.
⚠ 규율: FY2018~20 특별배당은 원문이 '資本水準調整のための一時的な配当'(자본 수준 조정용 일시 배당)이라 적은 금액(분할 전 70·35·35엔). 배당정책 원문: 「配当を基本として株主還元の充実に努める」.
⚠ Discipline: The FY2018–20 special dividends are the amounts the filing calls 'one-off dividends for capital-level adjustment' (pre-split JPY 70 · 35 · 35). Dividend policy, in the company's words: to enhance shareholder returns with dividends as the basis.
Limitations: 분할 기준 소급은 우리 계산(원문 DPS 는 분할 전 연도를 소급하지 않음) · 특별배당 = 원문 '資本水準調整のための一時的な配当'. Definitions: 1:3 split on 2022-10-01 applied to earlier years; source footnotes give the pre-split basis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: The split restatement is our calculation (the reported DPS does not restate pre-split years) · special dividend = what the filing calls a one-off dividend for capital-level adjustment. Definitions: 1:3 split on 2022-10-01 applied to earlier years; source footnotes give the pre-split basis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 分割基準への遡及は当サイト計算(原文のDPSは分割前の年度を遡及しない)· 特別配当 = 原文「資本水準調整のための一時的な配当」。 Definitions: 1:3 split on 2022-10-01 applied to earlier years; source footnotes give the pre-split basis.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
환원Returns還元Cash returned to shareholders vs. net incomeCash returned to shareholders vs. net income株主への現金還元 vs 純利益
⚠ 규율: FY2026 은 후발사건·ESR 문단에서 자사주 매입 연 4,000억엔 방침(Berkshire 몫 2,874억엔 별도)을 밝혔습니다 — 아래 '지분 구조'.
⚠ Discipline: For FY2026, the subsequent-event note and the ESR paragraph set out a buyback policy of JPY 400.0bn a year (JPY 287.4bn for Berkshire's portion separately) — see 'Ownership' below.
Limitations: 현금흐름표 기준(지급 시점) · FY2025 는 IFRS 재무제표 · FY2025 일본기준 순이익은 미감사. Definitions: cash-flow statement; FY2025 = IFRS statements; FY2025 J-GAAP net income unaudited.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Cash-flow statement basis (when paid) · FY2025 uses the IFRS statements · FY2025 J-GAAP net income is unaudited. Definitions: cash-flow statement; FY2025 = IFRS statements; FY2025 J-GAAP net income unaudited.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: キャッシュ・フロー計算書ベース(支払時点)· FY2025はIFRS財務諸表 · FY2025の日本基準純利益は未監査。 Definitions: cash-flow statement; FY2025 = IFRS statements; FY2025 J-GAAP net income unaudited.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
TSRFive-year total shareholder return vs. the Nikkei 225 (price) over the same five yearsFive-year total shareholder return vs. the Nikkei 225 (price) over the same five years5年TSR vs 同じ5年間の日経225(価格)
有報의 '株主総利回り'(배당 재투자, 5년 전=100) vs 닛케이225 가격지수의 같은 5년 변화(회계연도 말 종가). FY2025 493 vs 175.
The annual report's total shareholder return (dividends reinvested, five years earlier = 100) vs the Nikkei 225 price index's change over the same five years (fiscal year-end closes). FY2025 493 vs 175.
有報の「株主総利回り」(配当再投資、5年前=100)vs 日経225価格指数の同じ5年間の変化(会計年度末の終値)。FY2025 493 vs 175。
⚠ 규율: 각 연도 값은 그해 有報 표의 마지막 칸 — 5년 누적이라 연도끼리 더하면 안 됩니다. 有報 표의 비교 지수(TOPIX)는 JPX 라이선스를 확인하지 못해 싣지 않았고, 닛케이225 는 배당이 빠진 가격지수라 같은 조건의 비교가 아닙니다.
⚠ Discipline: Each year's value is the last column of that year's annual-report table — five-year cumulative, so years must not be added together. The table's comparison index (TOPIX) is not shown because the JPX licence could not be confirmed, and the Nikkei 225 is a price index without dividends, so this is not a like-for-like comparison.
Limitations: 도쿄해상 TSR = 有報 표(배당 재투자, 5년 전 = 100) · 닛케이225 는 가격지수(배당 제외)라 같은 기간 총수익보다 낮게 나온다 · 닛케이225 5년 변화는 회계연도 말(3월 마지막 거래일) 종가로 우리가 계산. Definitions: Tokio Marine as printed in each annual report; Nikkei 225 from fiscal year-end closes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Tokio Marine TSR = table in the annual securities report (dividends reinvested, five years earlier = 100) · the Nikkei 225 is a price index (dividends excluded), so it comes out below total return over the same period · the Nikkei 225 five-year change is our calculation from fiscal year-end closes (last trading day of March). Definitions: Tokio Marine as printed in each annual report; Nikkei 225 from fiscal year-end closes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Tokio MarineのTSR = 有報の表(配当再投資、5年前 = 100)· 日経225は価格指数(配当除く)のため同期間のトータルリターンより低く出る · 日経225の5年変化は会計年度末(3月最終取引日)の終値から当サイトが計算。 Definitions: Tokio Marine as printed in each annual report; Nikkei 225 from fiscal year-end closes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
08
도쿄해상 — 성장: 보험료·보험수익·이익(회사 KPI 수정순이익 포함)Tokio Marine — growth: premiums, insurance revenue and profit (incl. the company KPI, adjusted net income)Tokio Marine — 成長:保険料・保険収益・利益(会社KPIの修正純利益を含む)
매출Top line売上Net premiums written (J-GAAP) and insurance revenue (IFRS)Net premiums written (J-GAAP) and insurance revenue (IFRS)正味収入保険料(日本基準)と保険収益(IFRS)
⚠ 규율: 엔화 약세가 해외 보험료를 엔으로 부풀립니다(해외 비중이 절반) — 현지통화 성장률은 有報에 없습니다.
⚠ Discipline: Yen weakness inflates overseas premiums in yen terms (overseas is about half) — local-currency growth is not in the annual securities report.
Limitations: 엔화 약세가 해외 보험료를 엔으로 부풀린다 — 현지통화 성장률은 有報에 없다 · FY2025 일본기준 값은 참고표(미감사). Definitions: consolidated; FY2025 J-GAAP figure from the annual report's reference table (unaudited).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Yen weakness inflates overseas premiums in yen terms — local-currency growth is not in the annual securities report · FY2025 J-GAAP figures come from a reference table (unaudited). Definitions: consolidated; FY2025 J-GAAP figure from the annual report's reference table (unaudited).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 円安が海外保険料を円建てで膨らませる — 現地通貨ベースの成長率は有報にない · FY2025の日本基準の値は参考表(未監査)。 Definitions: consolidated; FY2025 J-GAAP figure from the annual report's reference table (unaudited).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
이익Earnings利益Net income: J-GAAP vs. IFRS vs. the company's adjusted net incomeNet income: J-GAAP vs. IFRS vs. the company's adjusted net income純利益:日本基準 vs IFRS vs 会社の修正純利益
⚠ 규율: 수정순이익은 비GAAP 입니다. 일본기준 정의 = 순이익 + 이상위험준비금·가격변동준비금 등 적립액 − ALM 채권 손익 − 사업투자 손익 …(有報 経営方針). FY2021 정의 변경(FY2020 은 옛 정의 3,361억 / 새 정의 3,996억). FY2026 부터 IFRS 정의 — 계획 9,500억엔·수정ROE 13.0%.
⚠ Discipline: Adjusted net income is non-GAAP. J-GAAP definition = net income + provisions to catastrophe reserves, price-fluctuation reserves etc. − ALM bond gains/losses − business-investment gains/losses … (annual report, management policy). Definition revised in FY2021 (FY2020 on the old definition JPY 336.1bn / on the new definition JPY 399.6bn). IFRS definition from FY2026 — plan JPY 950.0bn · adjusted ROE 13.0%.
Limitations: 수정순이익은 회사 KPI(비GAAP) · FY2021 정의 변경 · FY2026 부터 IFRS 정의. Definitions: adjusted = company definition (J-GAAP based through FY2025; definition revised from FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Adjusted net income is a company KPI (non-GAAP) · definition revised in FY2021 · IFRS definition from FY2026. Definitions: adjusted = company definition (J-GAAP based through FY2025; definition revised from FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 修正純利益は会社KPI(非GAAP)· FY2021に定義変更 · FY2026からIFRS定義。 Definitions: adjusted = company definition (J-GAAP based through FY2025; definition revised from FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
ROEReturn on equity: J-GAAP vs. IFRS vs. company-adjustedReturn on equity: J-GAAP vs. IFRS vs. company-adjustedROE:日本基準 vs IFRS vs 会社の修正
FY2025: 일본기준 ROE 18.7% · 수정ROE 22.0% · IFRS ROE 7.1%. 분자: 순이익 일본기준 0.98조엔 vs IFRS 0.53조엔 (정책주식 처분익이 IFRS 손익을 건너뜀). 분모: 일본기준 순자산 5.46조엔 vs IFRS 자본 7.96조엔 (이상위험준비금 등이 IFRS 에선 자본). 회사 계획 FY2026 수정ROE 13.0%(IFRS 정의).
FY2025: J-GAAP ROE 18.7% · adjusted ROE 22.0% · IFRS ROE 7.1%. Numerator: net income J-GAAP JPY 0.98trn vs IFRS JPY 0.53trn (gains on disposing of policy stocks bypass IFRS profit and loss). Denominator: J-GAAP net assets JPY 5.46trn vs IFRS equity JPY 7.96trn (catastrophe reserves etc. are equity under IFRS). Company plan for FY2026: adjusted ROE 13.0% (IFRS definition).
FY2025:日本基準ROE 18.7% · 修正ROE 22.0% · IFRS ROE 7.1%。分子:純利益 日本基準0.98兆円 vs IFRS 0.53兆円(政策株式の処分益はIFRSの損益を通らない)。分母:日本基準の純資産5.46兆円 vs IFRS資本7.96兆円(異常危険準備金などはIFRSでは資本)。会社計画 FY2026の修正ROE 13.0%(IFRS定義)。
⚠ 규율: FY2025 일본기준 ROE 는 미감사 참고치. FY2020 수정ROE 는 새 정의 11.3%(옛 정의 9.7%). 회사 문장(IFRS 주석 10): 「ROEをグローバルピア水準まで引き上げる」.
⚠ Discipline: FY2025 J-GAAP ROE is an unaudited reference value. FY2020 adjusted ROE is 11.3% on the new definition (9.7% on the old). The company's wording (IFRS note 10): to raise ROE to the level of global peers.
Limitations: 세 ROE 는 분자(정책주식 처분익)와 분모(준비금의 자본 인식)가 다르다 · 수정ROE 는 회사 KPI. Definitions: J-GAAP and IFRS as printed in the annual report; adjusted = company KPI (definition revised FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: The three ROEs differ in the numerator (gains on disposing of policy stocks) and in the denominator (reserves recognised as equity) · adjusted ROE is a company KPI. Definitions: J-GAAP and IFRS as printed in the annual report; adjusted = company KPI (definition revised FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 3つのROEは分子(政策株式の処分益)と分母(準備金の資本認識)が異なる · 修正ROEは会社KPI。 Definitions: J-GAAP and IFRS as printed in the annual report; adjusted = company KPI (definition revised FY2021).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
세그먼트SegmentsセグメントOrdinary profit by segment, J-GAAP (FY2017–FY2024)Ordinary profit by segment, J-GAAP (FY2017–FY2024)セグメント別経常利益、日本基準(FY2017〜FY2024)
FY2024: Domestic P&C 0.89조엔 · Domestic life 0.07조엔 · International 0.49조엔 · Financial & other 0.01조엔. 국내손보 경상이익의 급증(FY2024)은 원문 MD&A 「政策株式売却益が増加したことを主因として」.
FY2024: Domestic P&C JPY 0.89trn · Domestic life JPY 0.07trn · International JPY 0.49trn · Financial & other JPY 0.01trn. The jump in domestic P&C ordinary profit (FY2024) was, per the MD&A, mainly due to higher gains on sales of policy stocks.
⚠ 규율: 세그먼트 경상이익 = 経常利益(일본기준). 네 칸 합과 합계는 백만엔 미만 절사로 최대 4백만엔 어긋납니다(검증에서 허용).
⚠ Discipline: Segment ordinary profit = ordinary profit (J-GAAP). The sum of the four columns and the total differ by up to JPY 4mn because amounts under JPY 1mn are truncated (allowed in the checks).
Limitations: 일본기준 세그먼트 경상이익(세그먼트 간 조정 전) · FY2025 부터 IFRS 라 이 표가 없다. Definitions: segment ordinary profit before inter-segment adjustments.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: J-GAAP segment ordinary profit (before inter-segment adjustments) · this table does not exist from FY2025 because of the switch to IFRS. Definitions: segment ordinary profit before inter-segment adjustments.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 日本基準のセグメント経常利益(セグメント間調整前)· FY2025からIFRSのためこの表はない。 Definitions: segment ordinary profit before inter-segment adjustments.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
IFRS 세그먼트IFRS segmentsIFRSセグメントIFRS segments: insurance revenue and insurance service result (FY2024 restated, FY2025)IFRS segments: insurance revenue and insurance service result (FY2024 restated, FY2025)IFRSセグメント:保険収益と保険サービス損益(FY2024再表示、FY2025)
⚠ 규율: 국내생보 금융손익이 음수(-0.39조엔)인 건 보험금융비용(할인율 부리)이 투자손익보다 큰 구조 — 일본기준엔 없던 줄입니다.
⚠ Discipline: The domestic life finance result is negative (JPY -0.39trn) because insurance finance expense (interest accreted at the discount rate) exceeds the investment result — a line that did not exist under J-GAAP.
Limitations: IFRS 두 해(FY2024 재작성 · FY2025)뿐. Definitions: insurance service result = revenue − service expenses + reinsurance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Only two IFRS years (FY2024 restated · FY2025). Definitions: insurance service result = revenue − service expenses + reinsurance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRSは2年(FY2024再表示・FY2025)のみ。 Definitions: insurance service result = revenue − service expenses + reinsurance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
종목Lines種目Net premiums written by line, FY2024: domestic P&C vs. internationalNet premiums written by line, FY2024: domestic P&C vs. international種目別の正味収入保険料(FY2024):国内損保 vs 海外
국내손보 합계 2.71조엔 중 자동차 1.29조엔 (48%). 해외 합계 2.60조엔 중 '기타'(배상책임·전문보험 등) 1.23조엔 (47%).
Of domestic P&C's total JPY 2.71trn, auto is JPY 1.29trn (48%). Of international's total JPY 2.60trn, 'other' (liability, specialty lines, etc.) is JPY 1.23trn (47%).
Limitations: MD&A 표(세그먼트 간 제거 전) · FY2024 가 마지막 일본기준 연도. Definitions: MD&A tables before inter-segment elimination; CALI = compulsory auto liability (Japan only).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&A tables (before inter-segment elimination) · FY2024 is the last J-GAAP year. Definitions: MD&A tables before inter-segment elimination; CALI = compulsory auto liability (Japan only).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&Aの表(セグメント間消去前)· FY2024が最後の日本基準の年度。 Definitions: MD&A tables before inter-segment elimination; CALI = compulsory auto liability (Japan only).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
대주주Major holders大株主Top-10 shareholders as of 2026-03-31 (annual report)Top-10 shareholders as of 2026-03-31 (annual report)上位10株主(2026-03-31時点、有報)
순위
주주(원문)
구분
주식수
지분
1
日本マスタートラスト信託銀行株式会社信託口
신탁(국내 기관 수탁)
321,356,000
17.09%
2
株式会社日本カストディ銀行信託口
신탁(국내 기관 수탁)
142,631,000
7.59%
3
STATE STREET BANK AND TRUST COMPANY 505001 (常任代理人株式会社みずほ銀行決済営業部)
해외 수탁·증권
66,592,000
3.54%
4
MOXLEY AND CO LLC (常任代理人株式会社三菱UFJ銀行)
해외 수탁·증권
34,270,000
1.82%
5
THE CHASE MANHATTAN BANK,N.A. LONDONSECS LENDING OMNIBUS ACCOUNT (常任代理人株式会社みずほ銀行決済営業部)
해외 수탁·증권
28,856,000
1.53%
6
東海日動従業員持株会
종업원 지주회
27,790,000
1.48%
7
明治安田生命保険相互会社(常任代理人株式会社日本カストディ銀行)
신탁(국내 기관 수탁)
26,973,000
1.43%
8
JP MORGAN CHASE BANK 385781 (常任代理人株式会社みずほ銀行決済営業部)
해외 수탁·증권
26,773,000
1.42%
9
ゴールドマン・サックス証券株式会社 BNYM (常任代理人株式会社三菱UFJ銀行)
해외 수탁·증권
22,249,000
1.18%
10
JP MORGAN CHASE BANK 385642 (常任代理人株式会社みずほ銀行決済営業部)
해외 수탁·증권
21,538,000
1.15%
Rank
Shareholder (as filed)
Type
Shares
Stake
1
日本マスタートラスト信託銀行株式会社信託口
Trust (domestic custodian)
321,356,000
17.09%
2
株式会社日本カストディ銀行信託口
Trust (domestic custodian)
142,631,000
7.59%
3
STATE STREET BANK AND TRUST COMPANY 505001 (常任代理人株式会社みずほ銀行決済営業部)
Overseas custodian / broker
66,592,000
3.54%
4
MOXLEY AND CO LLC (常任代理人株式会社三菱UFJ銀行)
Overseas custodian / broker
34,270,000
1.82%
5
THE CHASE MANHATTAN BANK,N.A. LONDONSECS LENDING OMNIBUS ACCOUNT (常任代理人株式会社みずほ銀行決済営業部)
Overseas custodian / broker
28,856,000
1.53%
6
東海日動従業員持株会
Employee shareholding association
27,790,000
1.48%
7
明治安田生命保険相互会社(常任代理人株式会社日本カストディ銀行)
Trust (domestic custodian)
26,973,000
1.43%
8
JP MORGAN CHASE BANK 385781 (常任代理人株式会社みずほ銀行決済営業部)
Overseas custodian / broker
26,773,000
1.42%
9
ゴールドマン・サックス証券株式会社 BNYM (常任代理人株式会社三菱UFJ銀行)
Overseas custodian / broker
22,249,000
1.18%
10
JP MORGAN CHASE BANK 385642 (常任代理人株式会社みずほ銀行決済営業部)
Overseas custodian / broker
21,538,000
1.15%
順位
株主(原文)
区分
株式数
持分
1
日本マスタートラスト信託銀行株式会社信託口
信託(国内機関の受託)
321,356,000
17.09%
2
株式会社日本カストディ銀行信託口
信託(国内機関の受託)
142,631,000
7.59%
3
STATE STREET BANK AND TRUST COMPANY 505001 (常任代理人株式会社みずほ銀行決済営業部)
海外カストディ・証券
66,592,000
3.54%
4
MOXLEY AND CO LLC (常任代理人株式会社三菱UFJ銀行)
海外カストディ・証券
34,270,000
1.82%
5
THE CHASE MANHATTAN BANK,N.A. LONDONSECS LENDING OMNIBUS ACCOUNT (常任代理人株式会社みずほ銀行決済営業部)
海外カストディ・証券
28,856,000
1.53%
6
東海日動従業員持株会
従業員持株会
27,790,000
1.48%
7
明治安田生命保険相互会社(常任代理人株式会社日本カストディ銀行)
信託(国内機関の受託)
26,973,000
1.43%
8
JP MORGAN CHASE BANK 385781 (常任代理人株式会社みずほ銀行決済営業部)
海外カストディ・証券
26,773,000
1.42%
9
ゴールドマン・サックス証券株式会社 BNYM (常任代理人株式会社三菱UFJ銀行)
海外カストディ・証券
22,249,000
1.18%
10
JP MORGAN CHASE BANK 385642 (常任代理人株式会社みずほ銀行決済営業部)
海外カストディ・証券
21,538,000
1.15%
상위 10 합계 38.2% — 1위는 日本マスタートラスト信託銀行(신탁구좌, 17.09%). 이름이 보이는 실질 주주는 종업원지주회(東海日動従業員持株会 1.48%)와 明治安田生命(1.43%) 정도입니다. 자기주식 53,937,600주 (2.79%).
Top-10 total 38.2% — the largest is 日本マスタートラスト信託銀行 (a trust account, 17.09%). The only named beneficial holders are roughly the employee shareholding association (東海日動従業員持株会, 1.48%) and 明治安田生命 (1.43%). Treasury shares 53,937,600 (2.79%).
⚠ 규율: 신탁구좌·해외 수탁은 명의일 뿐 실질 주주가 아닙니다. 한국 3사처럼 '최대주주 + 특수관계인' 지배 구조가 없습니다 — 그래서 지배력 대신 상호보유(아래)를 봐야 합니다.
⚠ Discipline: Trust accounts and overseas custodians are only holders of record, not beneficial owners. There is no 'largest shareholder + related parties' control structure as at the three Korean insurers — so look at cross-shareholdings (below) instead of control.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Holders of record (trust accounts, overseas custodians) — not beneficial owners.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
지분 추이Ownership trend持分の推移Largest nominee holder, top-10 total and treasury shares by periodLargest nominee holder, top-10 total and treasury shares by period期間別の筆頭名義株主・上位10合計・自己株式
상위 10 합계 28.5% (2019-03-31) → 38.2% (2026-03-31). 1위 신탁구좌 7.9% → 17.1%.
Top-10 total 28.5% (2019-03-31) → 38.2% (2026-03-31). Largest holder, a trust account, 7.9% → 17.1%.
Limitations: 有報·半期報告書 대주주 표 · 자기주식 비율은 매입·소각 시점에 따라 반기마다 출렁인다. Definitions: annual (FY) and half-year (H1) reports; x = fiscal period.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Major-shareholder tables in the annual and half-year securities reports · the treasury-share ratio swings each half-year with the timing of buybacks and cancellations. Definitions: annual (FY) and half-year (H1) reports; x = fiscal period.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 有報・半期報告書の大株主の表 · 自己株式比率は取得・消却の時期によって半期ごとに振れる。 Definitions: annual (FY) and half-year (H1) reports; x = fiscal period.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
BerkshireBerkshire Hathaway's National Indemnity: treasury-share allotment (subsequent event)Berkshire Hathaway's National Indemnity: treasury-share allotment (subsequent event)Berkshire HathawayのNational Indemnity:自己株式の第三者割当(後発事象)
後発事象(FY2025 有報): 2026-03-23 이사회가 Berkshire Hathaway 완전자회사 National Indemnity Company 와 전략적 제휴(전략적 출자·재보험 협업·M&A 공동투자)를 결의, 자기주식 48,207,200주를 1주 5,962엔(총 2,874억엔)에 제3자 배정 — 2026-04-13 납입 완료. 발행주식 1,934,000,000주 대비 2.49%. 희석을 막으려 같은 금액(2,874억엔 한도)의 자사주를 2026-04~09 에 사들이고, 별도로 2,000억엔(1억 3천만주 한도, 2026-05-21~12-23) 매입을 결의했습니다.
Subsequent event (FY2025 annual securities report): on 2026-03-23 the board resolved a strategic alliance (strategic investment, reinsurance cooperation, joint M&A investment) with National Indemnity Company, a wholly owned subsidiary of Berkshire Hathaway, and a third-party allotment of 48,207,200 treasury shares at JPY 5,962 per share (JPY 287.4bn in total) — paid in on 2026-04-13. That is 2.49% of the 1,934,000,000 shares issued. To offset the dilution it will buy back the same amount (up to JPY 287.4bn) of its own shares in 2026-04 to 09, and it separately resolved a buyback of JPY 200.0bn (up to 130 million shares, 2026-05-21 to 12-23).
⚠ 규율: 지분율은 有報의 발행주식수(2026-03말 1,934,000,000주)로 나눈 값입니다. 2026-09 반기보고서(11월 제출 예정)의 대주주 표에서 실제 순위를 확인해야 합니다. 5% 미만이라 대량보유보고서 의무는 없습니다.
⚠ Discipline: The stake is divided by the shares issued per the annual securities report (1,934,000,000 at end-March 2026). The actual ranking has to be checked in the major-shareholder table of the 2026-09 half-year report (due in November). Below 5%, so no large-shareholding report is required.
Limitations: 後発事象 원문 · 지분율은 2026-03말 발행주식 기준 우리 계산 · 실제 순위는 다음 반기보고서에서 확인해야 한다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Subsequent-event note in the filing · the stake is our calculation on shares issued at end-March 2026 · the actual ranking has to be checked in the next half-year report.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
NICO 가격NICO priceNICO価格Yields at National Indemnity's price (5,962 yen) vs. 10Y sovereignsYields at National Indemnity's price (5,962 yen) vs. 10Y sovereignsNational Indemnityの取得価格(5,962円)での利回り vs 10年国債
⚠ 규율: 제 계산(수익률 = ROE ÷ P/B). 수정ROE 는 회사 계획치·비GAAP. 처분가 5,962엔은 3월말 역산 주가 7,309엔보다 18% 낮습니다 — 결의일(3/23) 전후 시세는 Raw Data 에 없어 원인은 확인하지 못했습니다. 동기에 대한 판단은 사용자 몫.
⚠ Discipline: Our calculation (yield = ROE ÷ P/B). Adjusted ROE is a company plan figure and non-GAAP. The allotment price of JPY 5,962 is 18% below the backed-out March-end price of JPY 7,309 — prices around the resolution date (3/23) are not in the Raw Data, so the cause could not be confirmed. The judgement on motives is the reader's.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 수정ROE 는 회사 계획치·비GAAP · 수익률 = ROE ÷ P/B 는 우리 계산 · 결의일 전후 시세는 Raw Data 에 없다. Definitions: FY2025 per-share figures ÷ 5,962 yen; Adj. ROE/PB = FY2026 plan adjusted ROE ÷ (price ÷ adjusted BVPS); sovereigns at 2026-03-31.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Adjusted ROE is a company plan figure and non-GAAP · yield = ROE ÷ P/B is our calculation · prices around the resolution date are not in the Raw Data. Definitions: FY2025 per-share figures ÷ 5,962 yen; Adj. ROE/PB = FY2026 plan adjusted ROE ÷ (price ÷ adjusted BVPS); sovereigns at 2026-03-31.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
상호보유Cross-holdings相互保有Specified policy holdings whose issuer also holds Tokio Marine shares (cross-shareholding)Specified policy holdings whose issuer also holds Tokio Marine shares (cross-shareholding)発行体もTokio Marine株を保有する特定投資株式(相互保有)
특정투자주식 중 상대도 도쿄해상 주식을 가진 종목(当社の株式の保有の有無 = 有): FY2018 101 → FY2025 50. FY2018 상위의 도요타·미쓰비시상사·혼다·가오·미쓰비시지소는 모두 '有'였고, FY2025 도요타는 '無'.
Specified investment shares whose issuer also holds Tokio Marine shares (the filing's 'holds the company's shares' = yes): FY2018 101 → FY2025 50. Among the top FY2018 holdings, Toyota, Mitsu Corp, Honda, Kao and Mitsu Est. were all 'yes'; in FY2025, Toyota is 'no'.
⚠ 규율: 공시는 '최대 보유회사'(東京海上日動) 기준입니다. FY2018 대주주 8위가 「退職給付信託口・三菱商事株式会社口」(1.5%)였던 것 — 미쓰비시상사가 퇴직급여신탁으로 도쿄해상 주식을 보유했고 도쿄해상도 미쓰비시상사 주식을 보유했습니다(쌍방).
⚠ Discipline: The disclosure is for the 'largest holding company' (Tokio Marine & Nichido). In FY2018 the No. 8 major shareholder was 「退職給付信託口・三菱商事株式会社口」 (1.5%) — Mitsu Corp held Tokio Marine shares through a retirement-benefit trust, and Tokio Marine also held Mitsu Corp shares (both ways).
Limitations: 최대 보유회사(東京海上日動) 공시 기준 · 상호보유 = 원문 '当社の株式の保有の有無' 가 有. Definitions: specified investment shares of the largest holding company; issuer holds Tokio Marine shares = yes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Based on the disclosure of the largest holding company (Tokio Marine & Nichido) · cross-shareholding = 'yes' in the filing's column on whether the issuer holds the company's shares. Definitions: specified investment shares of the largest holding company; issuer holds Tokio Marine shares = yes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 最大保有会社(東京海上日動)の開示ベース · 相互保有 = 原文「当社の株式の保有の有無」が有。 Definitions: specified investment shares of the largest holding company; issuer holds Tokio Marine shares = yes.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 최대 보유회사(東京海上日動) 공시 기준 · 장부가 = 기말 공정가치. Definitions: book value = fair value at year-end; red = issuer also holds Tokio Marine shares.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Based on the disclosure of the largest holding company (Tokio Marine & Nichido) · book value = year-end fair value. Definitions: book value = fair value at year-end; red = issuer also holds Tokio Marine shares.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 最大保有会社(東京海上日動)の開示ベース · 簿価 = 期末の公正価値。 Definitions: book value = fair value at year-end; red = issuer also holds Tokio Marine shares.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
삼성화재Samsung F&MSamsung F&MCross-border link: Tokio Marine & Nichido's stake in Samsung Fire & MarineCross-border link: Tokio Marine & Nichido's stake in Samsung Fire & Marine国境を越えたつながり:東京海上日動によるSamsung F&M株式の保有
도쿄해상일동은 삼성화재 보통주 1,488,150주(장부 687억엔, FY2025 말)를 보유합니다. 삼성화재 발행주식(소각 후) 44,647,473주(2026H1 기준, DART Raw Data) 대비 3.33%. 보유 목적 원문: 「海外保険事業における投資先とのパートナーシップ構築・強化を目的として、保有しているものです。 同社、The People's Insurance Company (Group) of China Limitedおよび当社の3社提携に基づき、」. 상대는 도쿄해상 주식을 보유하지 않습니다('無').
Tokio Marine & Nichido holds 1,488,150 common shares of Samsung F&M (book value JPY 68.7bn, end-FY2025). That is 3.33% of Samsung F&M's 44,647,473 shares issued (after cancellations; as of 2026H1, DART Raw Data). Purpose of holding, original: 「海外保険事業における投資先とのパートナーシップ構築・強化を目的として、保有しているものです。 同社、The People's Insurance Company (Group) of China Limitedおよび当社の3社提携に基づき、」. The issuer does not hold Tokio Marine shares ('no').
東京海上日動はSamsung F&Mの普通株式1,488,150株(簿価687億円、FY2025末)を保有する。Samsung F&Mの発行済株式(消却後)44,647,473株(2026H1時点、DARTのRaw Data)に対し3.33%。保有目的の原文:「海外保険事業における投資先とのパートナーシップ構築・強化を目的として、保有しているものです。 同社、The People's Insurance Company (Group) of China Limitedおよび当社の3社提携に基づき、」。相手はTokio Marine株を保有していない(「無」)。
⚠ Discipline: Reference dates differ (Tokio Marine share count at end-March 2026 · Samsung F&M share count from the latest period of the DART total-shares table). Below 5%, so it does not appear in Samsung F&M's largest-shareholder table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Reference dates differ (Tokio Marine share count at end-March 2026 · Samsung F&M share count from the latest period of the DART total-shares table).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
10
도쿄해상 — 정책보유주식: 유보된 돈이 굴러가는 구조Tokio Marine — policy shareholdings: how retained money is put to workTokio Marine — 政策保有株式:内部留保が回る仕組み
잔고·매각Book & sales残高・売却Listed policy holdings: book value and sale proceeds of reduced names (largest holding company)Listed policy holdings: book value and sale proceeds of reduced names (largest holding company)上場の政策保有株式:簿価と減少銘柄の売却額(最大保有会社)
⚠ 규율: 원문 방침(2024-05 이사회 결정): 「2029年度末までにゼロにします」 — 비상장·자본업무제휴 출자는 제외. FY2025 는 「年間で7,456億円と計画を上回る水準で削減」, 잔고는 IFRS 연결 순자산의 24.5%(2026년도 말 20% 내외 목표).
⚠ Discipline: Policy in the company's words (board decision, 2024-05): reduce them to zero by the end of FY2029 — excluding unlisted holdings and capital and business-alliance investments. In FY2025 they were cut by JPY 745.6bn in the year, more than planned, and the balance is 24.5% of IFRS consolidated net assets (target around 20% by the end of FY2026).
Limitations: 최대 보유회사 기준 · 감소 종목의 매각 대가는 회사 기재값. Definitions: shareholdings held for purposes other than pure investment.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Largest-holding-company basis · sale proceeds of reduced names are company-reported values. Definitions: shareholdings held for purposes other than pure investment.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 最大保有会社ベース · 減少銘柄の売却額は会社開示値。 Definitions: shareholdings held for purposes other than pure investment.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
종목 수Names銘柄数Number of listed policy-holding namesNumber of listed policy-holding names上場の政策保有銘柄数
상장 정책보유 종목 수 FY2018 1,120 → FY2025 563. 비상장 681종목(장부 0.04조엔)은 축소 대상에서 빠집니다.
Number of listed policy-holding names FY2018 1,120 → FY2025 563. The 681 unlisted names (book value JPY 0.04trn) are outside the reduction target.
Limitations: 최대 보유회사 기준 · 상장 정책보유 종목 수(기말). Definitions: year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Largest-holding-company basis · number of listed policy-holding names (year-end). Definitions: year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
평가차익Unrealised gains評価差益Available-for-sale stocks: book value vs. acquisition cost (consolidated, J-GAAP)Available-for-sale stocks: book value vs. acquisition cost (consolidated, J-GAAP)その他有価証券の株式:簿価 vs 取得原価(連結、日本基準)
주식 평가차익(장부 − 취득원가): FY17 2.01조엔, FY18 1.78조엔, FY19 1.41조엔, FY20 1.94조엔, FY21 2.01조엔, FY22 1.91조엔, FY23 3.07조엔, FY24 1.78조엔. FY2024 취득원가는 장부가의 16%뿐 — 수십 년 전 원가로 들고 있던 주식입니다.
Unrealised gains on stocks (book − cost): FY17 JPY 2.01trn, FY18 JPY 1.78trn, FY19 JPY 1.41trn, FY20 JPY 1.94trn, FY21 JPY 2.01trn, FY22 JPY 1.91trn, FY23 JPY 3.07trn, FY24 JPY 1.78trn. In FY2024, acquisition cost was only 16% of book value — shares held at costs from decades ago.
⚠ 규율: 백만엔 표를 조엔으로 환산. FY2022 는 FY2023 有報에서 해외 자회사 IFRS 17 소급으로 외국증권·기타가 재표시됐습니다(국내 주식은 동일).
⚠ Discipline: Tables in JPY mn converted to JPY trn. FY2022 was restated in the FY2023 annual report for foreign securities and others because of the retrospective IFRS 17 application at overseas subsidiaries (domestic stocks unchanged).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: J-GAAP available-for-sale stocks (consolidated) · gap = unrealised gain. Definitions: securities note, available-for-sale stocks; gap = unrealized gain.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
매각익Sale gains売却益Stocks sold: proceeds vs. realized gains (J-GAAP through FY2024; IFRS FY2025 = gain bypasses profit)Stocks sold: proceeds vs. realised gains (J-GAAP through FY2024; IFRS FY2025 = gain bypasses profit)株式の売却:売却額 vs 実現益(FY2024までは日本基準、FY2025のIFRSでは利益が損益を通らない)
주식 매각액·매각익(일본기준): FY2023 0.22조엔·0.19조엔 → FY2024 0.92조엔·0.81조엔 (매각액의 88%가 이익). IFRS FY2025: 처분 시 공정가치 0.78조엔 · 처분 누적이익 0.66조엔 — 이 이익은 손익계산서를 거치지 않습니다(FVOCI).
Stock sale proceeds and gains (J-GAAP): FY2023 JPY 0.22trn · JPY 0.19trn → FY2024 JPY 0.92trn · JPY 0.81trn (88% of proceeds was gain). IFRS FY2025: fair value at disposal JPY 0.78trn · cumulative gain on disposal JPY 0.66trn — this gain does not pass through the income statement (FVOCI).
⚠ 규율: IFRS FY2024 비교치(처분 공정가치 0.94조엔 · 누적이익 0.81조엔)는 일본기준 FY2024 주식 매각(매각액 0.92조엔 · 매각익 0.81조엔)과 거의 같습니다 — 같은 거래를 두 기준으로 본 것.
⚠ Discipline: The IFRS FY2024 comparative (fair value at disposal JPY 0.94trn · cumulative gain JPY 0.81trn) is almost the same as the J-GAAP FY2024 stock sales (proceeds JPY 0.92trn · gains JPY 0.81trn) — the same transactions seen under two standards.
Limitations: 일본기준(FY2024 까지)은 매각익이 순이익으로 · IFRS(FY2025, FVOCI)는 이익잉여금으로 바로 간다 — 같은 줄로 잇지 않는다. Definitions: J-GAAP gains flow through net income; IFRS (FVOCI) gains go straight to retained earnings.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Under J-GAAP (through FY2024) sale gains go to net income · under IFRS (FY2025, FVOCI) they go straight to retained earnings — the two are not joined into one line. Definitions: J-GAAP gains flow through net income; IFRS (FVOCI) gains go straight to retained earnings.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 日本基準(FY2024まで)では売却益が純利益へ · IFRS(FY2025、FVOCI)では利益剰余金へ直接 — 同じ線でつながない。 Definitions: J-GAAP gains flow through net income; IFRS (FVOCI) gains go straight to retained earnings.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
IFRS 다리IFRS bridgeIFRSブリッジFY2024 net income, J-GAAP → IFRS: where 0.6 trillion yen wentFY2024 net income, J-GAAP → IFRS: where 0.6 trillion yen wentFY2024の純利益、日本基準 → IFRS:0.6兆円はどこへ行ったか
Net income attributable to owners of the parent: J-GAAP JPY 1.06trn → IFRS JPY 0.45trn (difference JPY -0.60trn). Investment result adjustment JPY -0.82trn (gains on selling policy stocks etc. treated as FVOCI), insurance service result JPY -0.32trn, insurance finance result JPY -0.53trn, G&A JPY 0.79trn (expenses treated as insurance acquisition cash flows).
⚠ Discipline: From the IFRS first-time adoption note's reconciliation of profit or loss (the recognition and measurement differences column). Presentation reclassifications are left out of the chart.
Limitations: IFRS 최초 적용 주석의 인식·측정 차이만 · 세전 항목, 세금은 따로. Definitions: recognition and measurement differences only (first-time adoption note).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Only the recognition and measurement differences in the IFRS first-time adoption note · pre-tax items, tax shown separately. Definitions: recognition and measurement differences only (first-time adoption note).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRS初度適用注記の認識・測定の差異のみ · 税引前の項目、税金は別。 Definitions: recognition and measurement differences only (first-time adoption note).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
유보금Retained留保金Retained earnings at IFRS transition (2024-04-01): what J-GAAP held backRetained earnings at IFRS transition (2024-04-01): what J-GAAP held backIFRS移行日(2024-04-01)の利益剰余金:日本基準が留保していたもの
IFRS 로 옮기자 이익잉여금이 3.46조엔 늘었습니다. 가장 큰 것은 보험계약 2.92조엔 — 일본기준의 보수적 책임준비금(이상위험준비금 등)이 IFRS 17 측정에서 자본으로 넘어간 크기입니다. 가격변동준비금(特別法上の準備金) 0.14조엔도 IFRS 에선 부채가 아닙니다(원문: 「IAS第37号…負債の定義を満たさない」).
Moving to IFRS raised retained earnings by JPY 3.46trn. The largest item is insurance contracts at JPY 2.92trn — the size of J-GAAP's conservative policy reserves (catastrophe reserves etc.) that moved into equity under IFRS 17 measurement. The price-fluctuation reserve (a statutory reserve under special laws) of JPY 0.14trn is not a liability under IFRS either (original: it does not meet the definition of a liability under IAS 37).
⚠ 규율: ESR 의 실질순자산도 같은 생각입니다 — FY2019 有報 원문: 「連結純資産に、異常危険準備金、価格変動準備金等の資本性負債…を加算」. 일본기준 장부에서 부채로 잡혀 있던 '유보금'이 경제적 자본으로 계산됩니다.
⚠ Discipline: The ESR's adjusted net assets follow the same idea — FY2019 annual report, original: catastrophe reserves, price-fluctuation reserves and other equity-like liabilities are added to consolidated net assets. The 'retained money' booked as liabilities under J-GAAP counts as economic capital.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
교환 산식Swap arithmetic交換の算式Policy stocks vs. own shares: what a yen earns in each (fiscal year-end 2025)Policy stocks vs. own shares: what a yen earns in each (fiscal year-end 2025)政策株式 vs 自己株式:1円がそれぞれ生むもの(会計年度末2025)
P/B 는 IFRS 1.73배로 장부보다 비쌉니다(한국 2사는 0.78~0.94배) — '자본 대비 저평가'는 숫자로 확인되지 않습니다. Raw Data 가 보여 주는 건 교환 산식입니다: 정책주식은 시가 대비 배당 1.70%(FY2025 · FY2024 2.29%)인데, 자기 주식은 3월말 주가 대비 이익수익률 IFRS 3.82% · 회사 계획 수정순이익 기준 6.91% · 일본기준 7.05%. 회사 원문(처분 목적): 「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」.
P/B is 1.73x on IFRS, above book (the two Korean insurers are at 0.78–0.94x) — 'undervalued relative to equity' is not borne out by the numbers. What the Raw Data shows is the swap arithmetic: policy stocks yield 1.70% in dividends on market value (FY2025 · FY2024 2.29%), while own shares yield, on the March-end price, 3.82% on IFRS earnings · 6.91% on the company's planned adjusted net income · 7.05% on J-GAAP. The company's wording (purpose of disposals): 「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」.
⚠ 규율: 비교 단위가 다릅니다: 정책주식은 현금 배당(시가 기준, 매각 차익 제외), 자기 주식은 회계 이익(현금 아님). 수정 기준 = FY2026 계획 수정순이익 9,500억엔 ÷ 유통주식 1,880,062,400주 = 505엔(제 계산). 매입 단가는 有報에 없습니다(총액만). 정책주식은 ESR 리스크량(주가 변동)도 씁니다 — 자본 효율 판단은 회사 문장 「修正ROEへの影響を考慮した上で事業投資や株主還元といった資本政策を決定」.
⚠ Discipline: The units differ: policy stocks give cash dividends (on market value, excluding sale gains), own shares give accounting earnings (not cash). Adjusted basis = FY2026 planned adjusted net income of JPY 950.0bn ÷ 1,880,062,400 shares outstanding = JPY 505 (our calculation). The buyback unit price is not in the annual securities report (totals only). Policy stocks also use up ESR risk capital (share-price moves) — on capital efficiency, the company's wording: capital policy, such as business investment and shareholder returns, is decided taking into account the impact on adjusted ROE.
Limitations: 정책주식 배당수익률 = FVOCI 주식 배당 ÷ 기말 공정가치 · 자기 주식 쪽은 역산 주가 기준 · 세금·거래비용·가격 영향은 따지지 않았다. Definitions: policy DY = dividends from FVOCI equities held ÷ their year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Policy-stock dividend yield = dividends on FVOCI equities ÷ year-end fair value · the own-share side uses the backed-out price · taxes, transaction costs and price impact are not considered. Definitions: policy DY = dividends from FVOCI equities held ÷ their year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 政策株式の配当利回り = FVOCI株式の配当 ÷ 期末公正価値 · 自己株式側は逆算株価ベース · 税金・取引コスト・価格への影響は考慮していない。 Definitions: policy DY = dividends from FVOCI equities held ÷ their year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
FVOCI 상위FVOCI topFVOCI上位Largest equity holdings designated at FVOCI (IFRS note): transition vs. FY2024 vs. FY2025Largest equity holdings designated at FVOCI (IFRS note): transition vs. FY2024 vs. FY2025FVOCI指定の株式の上位(IFRS注記):移行日 vs FY2024 vs FY2025
도요타: 이행일 9,682억엔 → FY2025 말 4,037억엔. 미쓰비시상사는 FY2025 상위 10에서 빠졌습니다.
Toyota: JPY 968.2bn at transition → JPY 403.7bn at end-FY2025. Mitsu Corp dropped out of the FY2025 top 10.
Limitations: 각 시점의 상위 10 종목만(빈칸 = 그 시점 상위 10 밖). Definitions: fair value; each date lists its own top 10 (blank = not in that date's top 10).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Only the top 10 names at each date (blank = outside that date's top 10). Definitions: fair value; each date lists its own top 10 (blank = not in that date's top 10).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 各時点の上位10銘柄のみ(空欄 = その時点の上位10外)。 Definitions: fair value; each date lists its own top 10 (blank = not in that date's top 10).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
11
도쿄해상 — 채권·운용자산 포트폴리오Tokio Marine — bond and invested-asset portfolioTokio Marine — 債券・運用資産ポートフォリオ
IFRS 투자IFRS investmentsIFRS投資Consolidated investments by type (IFRS note): transition, FY2024, FY2025Consolidated investments by type (IFRS note): transition, FY2024, FY2025種類別の連結投資(IFRS注記):移行日、FY2024、FY2025
일본 국채 등 7.77조엔 → 5.98조엔 → 4.20조엔 (-46%). 미국 국채 등 2.52조엔 → 2.85조엔 · 증권화상품 3.10조엔 → 4.39조엔 · 회사채 3.03조엔 → 3.65조엔.
Japanese government bonds etc. JPY 7.77trn → JPY 5.98trn → JPY 4.20trn (-46%). US government bonds etc. JPY 2.52trn → JPY 2.85trn · securitised products JPY 3.10trn → JPY 4.39trn · corporate bonds JPY 3.03trn → JPY 3.65trn.
⚠ 규율: FY2024 MD&A: 국내생보가 「保有契約の一部を再保険に出した」(보유계약 일부 재보험 출재) — 일본 국채 감소와 같은 해. 증권화상품은 해외(주로 미국) 자회사 보유분입니다.
⚠ Discipline: FY2024 MD&A: domestic life ceded part of its in-force business to reinsurers — the same year Japanese government bonds fell. Securitised products are held by overseas (mainly US) subsidiaries.
Limitations: IFRS 금융상품 주석 · 이행일·FY2024·FY2025 세 시점뿐. Definitions: consolidated; IFRS financial instruments note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRS financial-instruments note · only three dates: transition, FY2024 and FY2025. Definitions: consolidated; IFRS financial instruments note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
채권형인가Bond-like?債券型かBond fund or insurer? IFRS profit: underwriting vs. investment spreadBond fund or insurer? IFRS profit: underwriting vs. investment spread債券ファンドか保険会社か?IFRS利益:引受 vs 投資スプレッド
FY2025: 보험서비스손익 1.15조엔 vs 금융손익 순액 0.03조엔 — 이자수익 0.79조엔 가운데 보험금융비용(보험부채 할인율 부리) 0.68조엔이 계약자 몫으로 나갑니다. 재무상태표의 채권(부채성)은 17.55조엔, IFRS 자본 7.96조엔의 2.2배지만 주주에게 남는 건 스프레드입니다.
FY2025: insurance service result JPY 1.15trn vs net finance result JPY 0.03trn — of interest income of JPY 0.79trn, JPY 0.68trn goes out to policyholders as insurance finance expense (interest accreted at the insurance liability discount rate). Bonds (debt securities) on the balance sheet are JPY 17.55trn, 2.2x IFRS equity of JPY 7.96trn, but what is left for shareholders is the spread.
FY2025:保険サービス損益1.15兆円 vs 金融損益(純額)0.03兆円 — 利息収益0.79兆円のうち保険金融費用(保険負債の割引率による利息付与)0.68兆円が契約者の取り分として出ていく。貸借対照表の債券(負債性)は17.55兆円でIFRS資本7.96兆円の2.2倍だが、株主に残るのはスプレッドである。
⚠ 규율: IFRS 두 해뿐입니다. 일본기준 시절엔 이 분해가 없고(책임준비금 적립·운용수익이 한 손익계산서에 섞임), 정책주식 매각익이 '투자'에 들어갔습니다.
⚠ Discipline: Only two IFRS years. Under J-GAAP this breakdown did not exist (policy-reserve provisions and investment income were mixed in one income statement), and gains on selling policy stocks went into 'investment'.
Limitations: IFRS 두 해 · 이자수익 대부분이 보험금융비용(부채 할인율 부리)으로 계약자 몫. Definitions: interest earned on the portfolio is mostly passed to policyholder liabilities as insurance finance expense.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Two IFRS years · most interest income goes to policyholders as insurance finance expense (interest accreted at the liability discount rate). Definitions: interest earned on the portfolio is mostly passed to policyholder liabilities as insurance finance expense.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRSの2年 · 利息収益の大半は保険金融費用(負債の割引率による利息付与)として契約者の取り分。 Definitions: interest earned on the portfolio is mostly passed to policyholder liabilities as insurance finance expense.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
금리 민감도Rate sensitivity金利感応度Rates up: bond losses vs. liability gains in other comprehensive incomeRates up: bond losses vs. liability gains in other comprehensive income金利上昇:その他の包括利益における債券の損失 vs 負債の利益
FY2025: 채권 평가 -0.12조엔 · 보험부채 할인율 변동 0.33조엔 · 재보험 -0.04조엔 → 금리 관련 순액 0.17조엔. 같은 기간 JGB10Y 1.50% → 2.37% (3월말). JGB 가 크게 오른 해에는 부채가 채권보다 더 많이 줄어 자본이 늘었습니다. 단, 회사 민감도로는 모든 금리 +0.5%p 평행이면 자본 순 감소(아래 '질문과 답' Q12).
FY2025: bond revaluation JPY -0.12trn · change in insurance liability discount rates JPY 0.33trn · reinsurance JPY -0.04trn → rate-related net JPY 0.17trn. Over the same period JGB10Y 1.50% → 2.37% (end-March). In a year when JGB yields rose sharply, liabilities fell by more than bonds and equity rose. But on the company's sensitivity, a parallel +0.5pp move in all rates reduces equity net (see 'Questions and answers' Q12 below).
⚠ 규율: OCI 에는 신용스프레드·환율 영향도 섞여 있어 '금리만'의 효과는 아닙니다. 주식 FVOCI 는 정책주식 평가차익(처분 시 이익잉여금으로 직행).
⚠ Discipline: OCI also contains credit-spread and FX effects, so it is not a 'rates only' effect. Equity FVOCI is the unrealised gain on policy stocks (it goes straight to retained earnings on disposal).
Limitations: IFRS 기타포괄손익(세후) · 두 해뿐. Definitions: debt FVOCI = bond revaluation; insurance discount = liability revaluation when discount rates move.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRS other comprehensive income (after tax) · two years only. Definitions: debt FVOCI = bond revaluation; insurance discount = liability revaluation when discount rates move.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRSのその他の包括利益(税引後)· 2年のみ。 Definitions: debt FVOCI = bond revaluation; insurance discount = liability revaluation when discount rates move.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
유가증권Securities有価証券Domestic P&C (Tokio Marine & Nichido etc.): securities by typeDomestic P&C (Tokio Marine & Nichido etc.): securities by type国内損保(東京海上日動など):種類別の有価証券
FY2024: JGB 1.02조엔 (20.6%) · Municipal 263억엔 (0.5%) · Corporate 0.47조엔 (9.4%) · Stocks 2.16조엔 (43.8%) · Foreign sec. 1.23조엔 (25.0%) · Other 301억엔 (0.6%). 합계 FY2017 5.99조엔 → FY2024 4.94조엔.
FY2024: JGB JPY 1.02trn (20.6%) · Municipal JPY 26.3bn (0.5%) · Corporate JPY 0.47trn (9.4%) · Stocks JPY 2.16trn (43.8%) · Foreign sec. JPY 1.23trn (25.0%) · Other JPY 30.1bn (0.6%). Total FY2017 JPY 5.99trn → FY2024 JPY 4.94trn.
Limitations: MD&A 유가증권 표(세그먼트 간 제거 전) · 회사 분류 그대로. Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&A securities table (before inter-segment elimination) · the company's own classification. Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&Aの有価証券の表(セグメント間消去前)· 会社の分類どおり。 Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
유가증권Securities有価証券Domestic life (Anshin Life): securities by typeDomestic life (Anshin Life): securities by type国内生保(あんしん生命):種類別の有価証券
FY2024: JGB 5.84조엔 (81.4%) · Municipal 56억엔 (0.1%) · Corporate 0.53조엔 (7.3%) · Stocks 1억엔 (0.0%) · Foreign sec. 0.46조엔 (6.5%) · Other 0.34조엔 (4.7%). 합계 FY2017 6.71조엔 → FY2024 7.17조엔.
FY2024: JGB JPY 5.84trn (81.4%) · Municipal JPY 5.6bn (0.1%) · Corporate JPY 0.53trn (7.3%) · Stocks JPY 0.1bn (0.0%) · Foreign sec. JPY 0.46trn (6.5%) · Other JPY 0.34trn (4.7%). Total FY2017 JPY 6.71trn → FY2024 JPY 7.17trn.
⚠ 규율: 국내생보는 국채가 81.4% (FY2024) — 장기 부채와 듀레이션을 맞춘 ALM. FY2023 표는 원문 자체가 항목 합(83,456억엔)과 합계(83,451억엔)가 4.3억엔(428백만엔) 어긋납니다(두 해 有報 동일 — 원문 그대로 둠).
⚠ Discipline: Domestic life holds 81.4% in government bonds (FY2024) — ALM matched to the duration of long-term liabilities. The FY2023 table is itself inconsistent in the filing: the sum of items (JPY 8,345.6bn) and the total (JPY 8,345.1bn) differ by JPY 0.43bn (JPY 428mn) (the same in two years' annual reports — left as filed).
Limitations: MD&A 유가증권 표(세그먼트 간 제거 전) · 회사 분류 그대로. Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&A securities table (before inter-segment elimination) · the company's own classification. Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&Aの有価証券の表(セグメント間消去前)· 会社の分類どおり。 Definitions: MD&A securities table, before inter-segment elimination.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
해외 운용International assets海外運用International insurance: invested assets by typeInternational insurance: invested assets by type海外保険:種類別の運用資産
⚠ 규율: FY2024 MD&A 원문: 「米国で商業用不動産担保付貸付金にかかる予想信用損失が発生」 — 대출(상업용 부동산 담보)의 신용 리스크가 여기 있습니다. IFRS FY2025 부동산담보대출 2.07조엔.
⚠ Discipline: FY2024 MD&A, original: expected credit losses arose on loans secured by US commercial real estate — this is where the credit risk of loans (backed by commercial property) sits. IFRS FY2025 real-estate-secured loans JPY 2.07trn.
Limitations: MD&A 운용자산 표 · 회사 분류 그대로. Definitions: MD&A invested-assets table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&A invested-assets table · the company's own classification. Definitions: MD&A invested-assets table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
이율Yields利回りIncome yield on securities by segment vs. 10Y sovereignsIncome yield on securities by segment vs. 10Y sovereignsセグメント別の有価証券インカム利回り vs 10年国債
FY2024 유가증권 인컴 이율: 국내손보 5.13% · 국내생보 1.40% · 해외 3.72%. 국내손보 이율이 높은 건 원가가 낮은 정책주식 배당 때문입니다(분모가 취득원가).
FY2024 income yield on securities: domestic P&C 5.13% · domestic life 1.40% · international 3.72%. Domestic P&C's yield is high because of dividends on low-cost policy stocks (the denominator is acquisition cost).
⚠ 규율: 인컴 이율 = 이자·배당 수입 ÷ 평균 운용액(취득원가 기준) — 시가 기준 수익률이 아닙니다. 실현 이율(매각손익 포함)은 Raw Data 에 따로 있습니다.
⚠ Discipline: Income yield = interest and dividend income ÷ average invested amount (at cost) — not a market-value yield. The realised yield (incl. sale gains and losses) is kept separately in the Raw Data.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 이자·배당 ÷ 평균잔고(취득원가 기준, MD&A) — 시가 수익률이 아니다 · 국채는 회계연도 말. Definitions: interest & dividends ÷ average balance at cost (MD&A); sovereigns at fiscal year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Interest and dividends ÷ average balance (at cost, MD&A) — not a market-value yield · government bonds at fiscal year-end. Definitions: interest & dividends ÷ average balance at cost (MD&A); sovereigns at fiscal year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 利息・配当 ÷ 平均残高(取得原価ベース、MD&A)— 時価ベースの利回りではない · 国債は会計年度末。 Definitions: interest & dividends ÷ average balance at cost (MD&A); sovereigns at fiscal year-end.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
12
도쿄해상 — 건전성: 솔벤시 마진 비율·ESRTokio Marine — soundness: solvency margin ratio and ESRTokio Marine — 健全性:ソルベンシー・マージン比率・ESR
SMRSolvency margin ratio: group (consolidated) and Tokio Marine & Nichido (single)Solvency margin ratio: group (consolidated) and Tokio Marine & Nichido (single)ソルベンシー・マージン比率:グループ(連結)と東京海上日動(単体)
Consolidated SMR: FY17 879.3, FY18 854.2, FY19 845.8, FY20 896.5, FY21 827.3, FY22 627.5, FY23 652.8, FY24 590.8. Reason given in the filing (FY2024): mainly a fall in the consolidated solvency margin due to lower net unrealised gains on available-for-sale securities — sales of policy stocks reduced the unrealised gains (= the margin).
⚠ 규율: SMR 은 2026-03 말부터 일본의 경제가치 기준 규제(ESR)로 바뀌었습니다. FY2025 有報는 SMR 수치를 싣지 않습니다. 검증: 모든 표에서 A ÷ (B/2) 재계산이 기재값과 0.2pt 안(백만엔 절사).
⚠ Discipline: From end-March 2026 the SMR was replaced by Japan's economic-value-based regulation (ESR). The FY2025 annual securities report does not include SMR figures. Check: in every table, recomputing A ÷ (B/2) matches the reported value within 0.2pt (JPY mn truncation).
Limitations: 감독 기준 지급여력비율(회계연도 말). Definitions: regulatory minimum 200%; fiscal year-end; ratio = margin ÷ (risk ÷ 2).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Regulatory solvency margin ratio (fiscal year-end). Definitions: regulatory minimum 200%; fiscal year-end; ratio = margin ÷ (risk ÷ 2).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
ESREconomic solvency ratio (company internal, then the new regulatory basis)Economic solvency ratio (company internal, then the new regulatory basis)経済価値ベースのソルベンシー比率(会社内部、その後は新しい規制基準)
⚠ 규율: 2026-03 의 268%는 정의가 바뀐 값입니다(신뢰수준 99.95% → 99.5%, 목표 100–140% → ≥190%) — 2025-03 의 149%와 나란히 비교하면 안 됩니다. 원문: 「2026年3月末から日本国内において新資本規制(経済価値ベースのソルベンシー規制)が導入」.
⚠ Discipline: The 2026-03 figure of 268% is on a changed definition (confidence level 99.95% → 99.5%, target 100–140% → ≥190%) — do not compare it side by side with 2025-03's 149%. Original: a new capital regulation (economic-value-based solvency regulation) was introduced in Japan from end-March 2026.
Limitations: 회사 산출(내부 모형) — 2026-03 부터 새 규제 정의로 바뀌어 앞뒤가 같은 기준이 아니다. Definitions: 99.95% VaR through Mar 2025; * = 99.5% VaR from Mar 2026 (new definition).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Company-calculated (internal model) — switched to the new regulatory definition from 2026-03, so before and after are not on the same basis. Definitions: 99.95% VaR through Mar 2025; * = 99.5% VaR from Mar 2026 (new definition).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 会社算出(内部モデル)— 2026年3月から新しい規制上の定義に変わり、前後は同じ基準ではない。 Definitions: 99.95% VaR through Mar 2025; * = 99.5% VaR from Mar 2026 (new definition).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
13
도쿄해상 — 출처·이용조건·검증Tokio Marine — sources, terms of use and verificationTokio Marine — データ源・利用条件・検証
출처Sources出典Sources, license terms and verificationSources, licence terms and verificationデータ源・利用条件・検証
구분
건수
기간
有価証券報告書
8
2019-03-31 ~ 2026-03-31
半期報告書/四半期報告書(第2四半期)
7
2019-09-30 ~ 2025-09-30
四半期報告書(第1四半期)
5
2019-06-30 ~ 2023-06-30
四半期報告書(第3四半期)
5
2019-12-31 ~ 2023-12-31
Type
Count
Period
Annual securities report
8
2019-03-31 ~ 2026-03-31
Half-year report / Q2 quarterly report
7
2019-09-30 ~ 2025-09-30
Q1 quarterly report
5
2019-06-30 ~ 2023-06-30
Q3 quarterly report
5
2019-12-31 ~ 2023-12-31
区分
件数
期間
有価証券報告書
8
2019-03-31 ~ 2026-03-31
半期報告書/四半期報告書(第2四半期)
7
2019-09-30 ~ 2025-09-30
四半期報告書(第1四半期)
5
2019-06-30 ~ 2023-06-30
四半期報告書(第3四半期)
5
2019-12-31 ~ 2023-12-31
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) — 東京海上ホールディングス株式会社 提出書類 25건(有価証券報告書 第17期~第24期, 四半期報告書, 半期報告書; 2019-06-21~2026-06-26 提出). 加工:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東京海上ホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工). 国債:出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工) · Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates). 닛케이225:Source: brokerage HTS export (Nikkei 225). — 가격지수(배당 제외), 회계연도 말 종가. TOPIX 값은 싣지 않는다(JPX 지수 라이선스 미확인). BEI·物価連動国債(Q15):出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。 · 「10年物価連動」入札の最高利回り(実質)と「国債金利情報」の同残存期間の名目利回り(直線補間)の差をAdrenalin Babyが計算(Q15)(그림은 옮기지 않고 수치만 사용) · Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) — 東京海上ホールディングス株式会社 提出書類 25 filings (有価証券報告書 第17期~第24期, 四半期報告書, 半期報告書; filed 2019-06-21~2026-06-26). 加工:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東京海上ホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工). 国債:出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工) · Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates). Nikkei 225:Source: brokerage HTS export (Nikkei 225). — price index (dividends excluded), fiscal year-end closes. TOPIX values are not shown (JPX index licence not confirmed). BEI·物価連動国債(Q15):出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。 · 「10年物価連動」入札の最高利回り(実質)と「国債金利情報」の同残存期間の名目利回り(直線補間)の差をAdrenalin Babyが計算(Q15) (figures only; the chart itself is not reproduced) · Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) — 東京海上ホールディングス株式会社 提出書類 25件(有価証券報告書 第17期~第24期、四半期報告書、半期報告書;2019-06-21~2026-06-26 提出)。 加工:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東京海上ホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)。 国債:出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工) · Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates). 日経225:Source: brokerage HTS export (Nikkei 225). — 価格指数(配当除く)、会計年度末の終値。TOPIXの値は載せない(JPXの指数ライセンス未確認)。 BEI·物価連動国債(Q15):出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。 · 「10年物価連動」入札の最高利回り(実質)と「国債金利情報」の同残存期間の名目利回り(直線補間)の差をAdrenalin Babyが計算(Q15)(図は転載せず数値のみ使用)· Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
⚠ 규율: 이용조건(EDINET 利用規約, 2026-10-01 원문 확인): 출처 기재 · 가공 시 가공 사실과 주체 기재 · 가공물을 국가 원자료처럼 보이게 하지 않음 · 단시간 대량 접근 금지 · 자동 대량 수집 금지 · 통지 의무 없음. 검증: 369건 중 원문 자체 불일치 1(국내생보 FY2023 유가증권 합계).
⚠ Discipline: Terms of use (EDINET terms, original checked 2026-10-01): cite the source · when processing, state the fact of processing and who did it · do not make processed material look like the government's original data · no heavy access in a short time · no automated bulk collection · no notification required. Verification: of 369 checks, source-internal inconsistencies 1 (domestic life FY2023 securities total).
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 원천·이용조건·검증 요약(차트 아님).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: Summary of sources, terms of use and verification (not a chart).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: データ源・利用条件・検証の要約(チャートではない)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
14
4사 비교 — 같은 IFRS 17, 다른 이익 구조 (FY2025, 비율만)Four-company comparison — same IFRS 17, different profit structures (FY2025, ratios only)4社比較 — 同じIFRS 17、異なる利益構造(FY2025、比率のみ)
이익 원천Profit source利益の源泉Where operating profit comes from: insurance result vs. net investment result (% of insurance revenue)Where operating profit comes from: insurance result vs. net investment result (% of insurance revenue)営業利益の源泉:保険損益 vs 純投資損益(保険収益比、%)
영업이익 중 투자(순금융) 몫: 삼성화재 44% (FY2024 31%) · 현대해상 51% (FY2024 15%) · DB손보 52% (FY2024 29%) · 도쿄해상 2% (FY2024 3%). 한국 3사는 FY2025 에 보험손익 마진이 줄고(삼성 10.5→8.0% 등) 투자 몫이 절반 안팎으로 커졌습니다. 도쿄해상은 이자수익 대부분이 보험금융비용으로 계약자 몫이라 순금융손익이 보험수익의 0.3%뿐입니다.
Investment (net finance) share of operating profit: Samsung F&M 44% (FY2024 31%) · Hyundai M&F 51% (FY2024 15%) · DB Insurance 52% (FY2024 29%) · Tokio Marine 2% (FY2024 3%). In FY2025 the three Korean insurers' insurance margins fell (Samsung F&M 10.5→8.0%, etc.) and the investment share grew to around half. At Tokio Marine, most interest income goes to policyholders as insurance finance expense, so the net finance result is only 0.3% of insurance revenue.
⚠ 규율: 정의 차이: 한국 '보험손익'은 기타사업비용(비귀속 비용)까지 뺀 값, 도쿄해상 '보험서비스손익'은 일반관리비(FY2025 0.72조엔, 솔루션사업 포함)를 빼기 전 — 일반관리비를 빼면 5.5%(하한). 한국 투자손익 = 투자영업수익 − 투자영업비용(보험금융비용 포함)으로 Raw Data 에서 확인.
⚠ Discipline: Definitions differ: the Korean 'insurance result' is after other business expenses (non-attributable costs), while Tokio Marine's 'insurance service result' is before G&A (FY2025 JPY 0.72trn, incl. the solutions business) — after G&A it is 5.5% (lower bound). Korean investment result = investment operating revenue − investment operating expenses (incl. insurance finance expense), checked in the Raw Data.
Limitations: 정의 차이 — 한국 보험손익은 비귀속 비용까지 뺀 값, 도쿄해상 보험서비스손익은 일반관리비 차감 전 · 원·엔이 섞여 비율만 비교한다 · 기준일: 한국 3사 12월말, 도쿄해상 3월말. Definitions: Korea: insurance + investment result (net of ins. finance); Tokio Marine: service + finance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Definitions differ — the Korean insurance result is after non-attributable expenses, Tokio Marine's insurance service result is before G&A · won and yen are mixed, so only ratios are compared · reference dates: the three Korean insurers at end-December, Tokio Marine at end-March. Definitions: Korea: insurance + investment result (net of ins. finance); Tokio Marine: service + finance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 定義の違い — 韓国の保険損益は非帰属費用まで差し引いた値、Tokio Marineの保険サービス損益は一般管理費控除前 · ウォンと円が混在するため比率のみ比較 · 基準日:韓国3社は12月末、Tokio Marineは3月末。 Definitions: Korea: insurance + investment result (net of ins. finance); Tokio Marine: service + finance result.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
수익성·성장Profitability & growth収益性・成長Profitability and growth: ROE, pre-tax margin, insurance revenue growthProfitability and growth: ROE, pre-tax margin, insurance revenue growth収益性と成長:ROE、税引前マージン、保険収益の伸び
⚠ 규율: 현대해상 ROE 20.6%는 IFRS 17 자본이 얇아서(자본/보험수익 0.36배 vs 도쿄해상 1.03배)입니다. 도쿄해상 ROE 는 IFRS 기준 — 정책주식 처분익은 손익을 건너뜁니다(일본기준 18.7% · 수정 22.0%).
⚠ Discipline: Hyundai M&F's ROE of 20.6% reflects thin IFRS 17 equity (equity / insurance revenue 0.36x vs Tokio Marine 1.03x). Tokio Marine's ROE is on IFRS — gains on disposing of policy stocks bypass profit and loss (J-GAAP 18.7% · adjusted 22.0%).
⚠ 規律:Hyundai M&FのROE 20.6%はIFRS 17の資本が薄いため(資本/保険収益0.36倍 vs Tokio Marine 1.03倍)。Tokio MarineのROEはIFRSベース — 政策株式の処分益は損益を通らない(日本基準18.7% · 修正22.0%)。
Limitations: IFRS 17 연결 · 성장률은 현지통화(도쿄해상은 엔, 환율 효과 포함) · 기준일: 한국 3사 12월말, 도쿄해상 3월말. Definitions: IFRS 17 consolidated; growth = FY2025 vs FY2024 in local currency (Tokio Marine in yen, FX included).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRS 17 consolidated · growth in local currency (yen for Tokio Marine, FX effects included) · reference dates: the three Korean insurers at end-December, Tokio Marine at end-March. Definitions: IFRS 17 consolidated; growth = FY2025 vs FY2024 in local currency (Tokio Marine in yen, FX included).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRS 17連結 · 成長率は現地通貨(Tokio Marineは円、為替効果を含む)· 基準日:韓国3社は12月末、Tokio Marineは3月末。 Definitions: IFRS 17 consolidated; growth = FY2025 vs FY2024 in local currency (Tokio Marine in yen, FX included).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
국채 대비vs. sovereigns国債対比Shareholder yield vs. sovereigns: dividend and earnings yield spreadsShareholder yield vs. sovereigns: dividend and earnings yield spreads株主利回り vs 国債:配当利回り・益回りのスプレッド
삼성화재: DY 3.90% (자국 10Y 3.38%) · EY 9.5% · P/B 0.94배 · 현대해상: DY 0.00% (자국 10Y 3.38%) · EY n/a · P/B n/a · DB손보: DY 5.40% (자국 10Y 3.38%) · EY 21.0% · P/B 0.78배 · 도쿄해상: DY 2.98% (자국 10Y 2.37%) · EY 3.8% · P/B 1.73배.
Samsung F&M: DY 3.90% (home 10Y 3.38%) · EY 9.5% · P/B 0.94x · Hyundai M&F: DY 0.00% (home 10Y 3.38%) · EY n/a · P/B n/a · DB Insurance: DY 5.40% (home 10Y 3.38%) · EY 21.0% · P/B 0.78x · Tokio Marine: DY 2.98% (home 10Y 2.37%) · EY 3.8% · P/B 1.73x.
Samsung F&M:DY 3.90%(自国10年3.38%)· EY 9.5% · PBR 0.94倍 · Hyundai M&F:DY 0.00%(自国10年3.38%)· EY n/a · PBR n/a · DB Insurance:DY 5.40%(自国10年3.38%)· EY 21.0% · PBR 0.78倍 · Tokio Marine:DY 2.98%(自国10年2.37%)· EY 3.8% · PBR 1.73倍。
⚠ 규율: 같은 '손보주'인데 시장은 도쿄해상을 IFRS 이익의 26배·장부의 1.7배, 한국 2사를 장부 이하(P/B 0.94·0.78)로 값을 매겼습니다. 주가는 역산값(한국 = 배당기준일 전 1주 평균, 도쿄해상 = 3월말 EPS×PER).
⚠ Discipline: Same kind of 'P&C stock', yet the market priced Tokio Marine at 26x IFRS earnings and 1.7x book, and two of the Korean insurers below book (P/B 0.94 · 0.78). Prices are backed-out values (Korea = one-week average before the record date, Tokio Marine = March-end EPS × PER).
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 주가는 역산값 · 한국 12월말 · 도쿄해상 3월말 · 현대해상 무배당은 배당수익률 0, 주가 역산 불가. Definitions: home = KTB (Korea, Dec) / JGB (Tokio Marine, Mar); Hyundai paid no dividend: DY = 0, price not derivable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Prices are backed-out values · Korea at end-December · Tokio Marine at end-March · Hyundai M&F's no-dividend year: dividend yield 0, price cannot be backed out. Definitions: home = KTB (Korea, Dec) / JGB (Tokio Marine, Mar); Hyundai paid no dividend: DY = 0, price not derivable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 株価は逆算値 · 韓国は12月末 · Tokio Marineは3月末 · Hyundai M&Fの無配は配当利回り0、株価は逆算不可。 Definitions: home = KTB (Korea, Dec) / JGB (Tokio Marine, Mar); Hyundai paid no dividend: DY = 0, price not derivable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
한눈에At a glance一目でScorecard: the comparison table as charts (FY2025)Scorecard: the comparison table as charts (FY2025)スコアカード:比較表をチャートで(FY2025)
아래 표의 숫자를 지표별 막대로 옮겼습니다. 막대 색 = 회사(남색 삼성화재 · 적색 현대해상 · 황색 DB손보 · 청색 도쿄해상). 패널마다 축이 따로라 패널 간 길이 비교는 의미가 없습니다.
The numbers in the table below, turned into bars by metric. Bar colour = company (navy Samsung F&M · red Hyundai M&F · gold DB Insurance · blue Tokio Marine). Each panel has its own axis, so comparing bar lengths across panels is meaningless.
下の表の数字を指標別の棒に置き換えた。棒の色 = 会社(紺 Samsung F&M · 赤 Hyundai M&F · 黄 DB Insurance · 青 Tokio Marine)。パネルごとに軸が別なので、パネル間で棒の長さを比べても意味がない。
⚠ 규율: 현대해상: FY2025 무배당(원문 근거) → 배당수익률 0, 주가 역산 불가 → 이익수익률·P/B 없음. 도쿄해상 법정적립금은 IFRS 연결 장부에 없는 항목(자회사 일본기준 장부에 있음).
⚠ Discipline: Hyundai M&F: no dividend for FY2025 (per the filing) → dividend yield 0, price cannot be backed out → no earnings yield or P/B. Tokio Marine's statutory reserves are not an item in the IFRS consolidated accounts (they sit in the subsidiaries' J-GAAP books).
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 패널마다 축이 따로 · 자본비율은 K-ICS 와 ESR 로 체계가 다르다 · 포트폴리오 분류가 회사마다 다르다. Definitions: each panel has its own scale; ratios only (KRW and JPY not mixed); n/a = not derivable from the ledgers.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Each panel has its own axis · capital ratios are on different regimes (K-ICS vs ESR) · portfolio classifications differ by company. Definitions: each panel has its own scale; ratios only (KRW and JPY not mixed); n/a = not derivable from the ledgers.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: パネルごとに軸が別 · 資本比率はK-ICSとESRで制度が異なる · ポートフォリオの分類は会社ごとに異なる。 Definitions: each panel has its own scale; ratios only (KRW and JPY not mixed); n/a = not derivable from the ledgers.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
No controlling shareholder — the largest, a trust account, holds 17.1% · NICO (Berkshire) 2.5%
16.2% (FY2025 IFRS)
19.9%
—
会社
PBR
配当性向
資本比率
筆頭株主(支配)
株式の比率(有価証券)
自国国公債の比率
利益剰余金に占める法定積立金
Samsung F&M
0.94倍
41.1%
K-ICS 283% (2026H1)
삼성생명 15.9%(特別関係者合計19.6%)
44.4% (2026H1)
20.2%
47.5%
Hyundai M&F
n/a
0.0%
K-ICS 209% (2026H1)
정몽윤 23.1%(特別関係者合計24.0%)
4.6% (2026H1)
31.1%
65.5%
DB Insurance
0.78倍
25.7%
K-ICS 204% (2026H1)
김남호 9.7%(特別関係者合計27.6%)
10.1% (2026H1)
23.5%
63.2%
Tokio Marine
1.73倍
78.0%
ESR 268%(2026-03、会社算出)
支配株主なし — 筆頭は信託口17.1% · NICO(Berkshire)2.5%
16.2% (FY2025 IFRS)
19.9%
—
도쿄해상 배당성향 78%(IFRS EPS) + 자사주 매입 0.25조엔 → 주주환원이 IFRS 순이익의 118%. 한국은 배당성향 41.1% · 25.7% · 0.0%(현대해상 미실시), 이익잉여금 중 법정적립금(해약환급금·비상위험·대손준비금, 적립예정 포함) 비중 47.5% · 65.5% · 63.2% — 한국의 '유보'는 배당을 막고(현대해상), 일본의 '유보'(이상위험준비금 등)는 IFRS 연결 자본으로 넘어갔습니다(이행일 +2.92조엔, 세전).
Tokio Marine payout ratio 78% (IFRS EPS) + buybacks JPY 0.25trn → shareholder returns at 118% of IFRS net income. In Korea, payout ratios 41.1% · 25.7% · 0.0% (Hyundai M&F paid none), and statutory reserves (surrender-value, catastrophe and credit-loss reserves, incl. amounts to be reserved) as a share of retained earnings 47.5% · 65.5% · 63.2% — Korea's 'retention' blocks dividends (Hyundai M&F), while Japan's 'retention' (catastrophe reserves etc.) moved into IFRS consolidated equity (+JPY 2.92trn at transition, pre-tax).
⚠ 규율: 자본비율은 체계가 다릅니다: K-ICS(감독 표준모형, 경과조치 회사별) vs 도쿄해상 ESR(회사가 99.5% VaR 로 산출, 2026-03 일본 경제가치 규제 도입에 맞춰 정의 변경). 지주사 배당 여력은 자회사 일본기준 단체 장부(이상위험준비금 잔존)에 달려 있어 IFRS 자본 증가가 곧 배당 가능액은 아닙니다. 포트폴리오 분류도 다릅니다(한국 = 업무보고서 운용내역, 국공채+특수채 · 도쿄해상 = IFRS 금융상품 주석, 일본 국채 등).
⚠ Discipline: Capital ratios are on different regimes: K-ICS (supervisory standard model, transitional measures by company) vs Tokio Marine's ESR (calculated by the company at 99.5% VaR; definition changed with the introduction of Japan's economic-value-based regulation in 2026-03). The holding company's dividend capacity depends on the subsidiaries' J-GAAP single-entity books (where catastrophe reserves remain), so an increase in IFRS equity is not the same as distributable funds. Portfolio classifications also differ (Korea = business-report securities breakdown, govt & municipal + special bonds · Tokio Marine = IFRS financial-instruments note, Japanese government bonds etc.).
⚠ 規律:資本比率は制度が異なる:K-ICS(監督の標準モデル、経過措置は会社別)vs Tokio MarineのESR(会社が99.5% VaRで算出、2026年3月の日本の経済価値ベース規制の導入に合わせて定義変更)。持株会社の配当余力は子会社の日本基準の単体帳簿(異常危険準備金が残る)に左右されるため、IFRS資本の増加がそのまま配当可能額ではない。ポートフォリオの分類も異なる(韓国 = 業務報告書の運用内訳、国公債+特殊債 · Tokio Marine = IFRSの金融商品注記、日本国債など)。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Capital-ratio regimes (K-ICS vs ESR) and portfolio classifications differ · prices are backed-out values.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 資本比率の制度(K-ICS vs ESR)とポートフォリオの分類が異なる · 株価は逆算値。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
15
질문과 답 — 사용자 질문을 Raw Data 숫자로 다시 계산 (2026-10-01~02)Questions and answers — the user's questions, recomputed from Raw Data figures (2026-10-01–02)質問と回答 — 利用者の質問をRaw Dataの数字で再計算(2026-10-01〜02)
Q1도쿄해상에 투자하면 채권에 우회 투자하는 것인가?Is investing in Tokio Marine an indirect bet on bonds?Tokio Marineへの投資は債券への迂回投資なのか?
답: 재무상태표는 채권형, 손익은 보험형. 채권(부채성 증권) 17.55조엔 = IFRS 자본 7.96조엔의 2.2배, 그 돈의 원천은 보험계약부채 20.22조엔. 그런데 FY2025 보험서비스손익 1.15조엔 vs 금융손익 순액 0.03조엔 — 이자수익 0.79조엔 가운데 0.68조엔이 보험금융비용(부채 할인율 부리)으로 계약자 몫입니다.
Answer: a bond-like balance sheet, an insurance-like P&L. Bonds (debt securities) of JPY 17.55trn = 2.2x IFRS equity of JPY 7.96trn, funded by insurance contract liabilities of JPY 20.22trn. Yet in FY2025 the insurance service result was JPY 1.15trn vs a net finance result of JPY 0.03trn — of interest income of JPY 0.79trn, JPY 0.68trn goes to policyholders as insurance finance expense (interest accreted at the liability discount rate).
答え:貸借対照表は債券型、損益は保険型。債券(負債性証券)17.55兆円 = IFRS資本7.96兆円の2.2倍、その資金の源泉は保険契約負債20.22兆円。しかしFY2025の保険サービス損益1.15兆円 vs 金融損益(純額)0.03兆円 — 利息収益0.79兆円のうち0.68兆円が保険金融費用(負債の割引率による利息付与)として契約者の取り分である。
⚠ 규율: IFRS 두 해(FY2024 재작성·FY2025)뿐입니다. 4사 비교: 영업이익 중 투자 몫 한국 3사 44% · 51% · 52% vs 도쿄해상 2% — '채권형'에 가까운 건 오히려 한국 쪽.
⚠ Discipline: Only two IFRS years (FY2024 restated · FY2025). Four-company comparison: investment share of operating profit, the three Korean insurers 44% · 51% · 52% vs Tokio Marine 2% — if anything, it is the Korean side that is closer to 'bond-like'.
⚠ 規律:IFRSは2年(FY2024再表示・FY2025)のみ。4社比較:営業利益に占める投資の割合 韓国3社44% · 51% · 52% vs Tokio Marine 2% — 「債券型」に近いのはむしろ韓国側。
Limitations: IFRS 두 해뿐 · 보험금융비용 = 부채 할인율 부리. Definitions: interest earned on the bond book is mostly passed to policyholder liabilities.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Two IFRS years only · insurance finance expense = interest accreted at the liability discount rate. Definitions: interest earned on the bond book is mostly passed to policyholder liabilities.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: IFRSは2年のみ · 保険金融費用 = 負債の割引率による利息付与。 Definitions: interest earned on the bond book is mostly passed to policyholder liabilities.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q2버핏(Berkshire)은 왜 주목하나? 단순히 배당 때문인가?Why is Buffett (Berkshire) interested? Is it simply the dividend?バフェット(Berkshire)はなぜ注目するのか?単に配当のためか?
답: 배당만으로는 설명되지 않습니다. 매입가 기준 배당수익률 3.66% < UST10Y 4.30%. 공시가 밝힌 제휴 축(원문): 「当社への戦略的出資、再保険分野における協働およびM&A等における戦略的提携」. Raw Data 가 보여 주는 다른 근거: 보험서비스손익 1.15조엔 · ESR 268%(목표 ≥190%) · 상장 정책보유 1.92조엔(2029년도 말까지 0으로 — 풀리는 자본) · 자사주 매입 연 4,000억엔(Berkshire 몫 별도).
Answer: the dividend alone does not explain it. Dividend yield at the purchase price 3.66% < UST10Y 4.30%. The pillars of the alliance stated in the disclosure (original): 「当社への戦略的出資、再保険分野における協働およびM&A等における戦略的提携」. Other evidence in the Raw Data: insurance service result JPY 1.15trn · ESR 268% (target ≥190%) · listed policy holdings JPY 1.92trn (to zero by the end of FY2029 — capital to be released) · buybacks of JPY 400.0bn a year (Berkshire's portion separate).
⚠ 규율: 처분가 5,962엔은 3월말 역산 주가 7,309엔보다 18% 낮습니다 — 결의일 전후 시세는 Raw Data 에 없어 원인 미확인. 지분 2.49%(발행주식 대비). 동기는 Raw Data 밖 — 판단은 사용자 몫.
⚠ Discipline: The allotment price of JPY 5,962 is 18% below the backed-out March-end price of JPY 7,309 — prices around the resolution date are not in the Raw Data, so the cause is unconfirmed. Stake 2.49% (of shares issued). The motive lies outside the Raw Data — the judgement is the reader's.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 처분가 기준 수익률은 우리 계산 · 수정ROE 는 회사 계획치·비GAAP. Definitions: FY2025 DPS and EPS ÷ allotment price; sovereigns at 2026-03-31; Adj. ROE/PB = FY2026 plan ÷ (price ÷ adjusted BVPS).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Yields at the allotment price are our calculation · adjusted ROE is a company plan figure and non-GAAP. Definitions: FY2025 DPS and EPS ÷ allotment price; sovereigns at 2026-03-31; Adj. ROE/PB = FY2026 plan ÷ (price ÷ adjusted BVPS).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 処分価格基準の利回りは当サイト計算 · 修正ROEは会社計画値・非GAAP。 Definitions: FY2025 DPS and EPS ÷ allotment price; sovereigns at 2026-03-31; Adj. ROE/PB = FY2026 plan ÷ (price ÷ adjusted BVPS).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q3ROE 와 ROI 는? (같은 해인데 왜 세 배 차이가 나나)What are the ROE and ROI? (Why a threefold gap in the same year?)ROEとROIは?(同じ年なのになぜ3倍も違うのか)
답: ROE 일본기준 18.7% · 수정 22.0% · IFRS 7.1%. 분자 — 순이익 일본기준 0.98조엔 vs IFRS 0.53조엔(정책주식 처분익이 IFRS 손익을 건너뜀). 분모 — 일본기준 순자산 5.46조엔 vs IFRS 자본 7.96조엔(이상위험준비금 등이 IFRS 에선 자본). NICO 매입가 기준 ROI: IFRS P/B 1.41배 → 5.01%, 수정순자산 기준 P/B 1.56배 × 계획 수정ROE 13.0% → 8.33%.
Answer: ROE J-GAAP 18.7% · adjusted 22.0% · IFRS 7.1%. Numerator — net income J-GAAP JPY 0.98trn vs IFRS JPY 0.53trn (gains on disposing of policy stocks bypass IFRS profit and loss). Denominator — J-GAAP net assets JPY 5.46trn vs IFRS equity JPY 7.96trn (catastrophe reserves etc. count as equity under IFRS). ROI at NICO's purchase price: IFRS P/B 1.41x → 5.01%; P/B on adjusted net assets 1.56x × planned adjusted ROE 13.0% → 8.33%.
⚠ 규율: ROI = ROE ÷ P/B 는 제 계산. 일본기준 FY2025 값은 미감사. 수정ROE 는 회사 KPI(비GAAP, FY2021 정의 변경, FY2026 부터 IFRS 정의).
⚠ Discipline: ROI = ROE ÷ P/B is our calculation. J-GAAP FY2025 figures are unaudited. Adjusted ROE is a company KPI (non-GAAP; definition revised in FY2021; IFRS definition from FY2026).
Limitations: ROI = ROE ÷ (가격 ÷ 장부) 는 우리 계산 · 수정 ROI 는 회사 계획치. Definitions: ROI = ROE ÷ (price ÷ book) at 5,962 yen; adjusted ROI uses the FY2026 plan (company KPI).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: ROI = ROE ÷ (price ÷ book) is our calculation · adjusted ROI uses the company plan figure. Definitions: ROI = ROE ÷ (price ÷ book) at 5,962 yen; adjusted ROI uses the FY2026 plan (company KPI).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: ROI = ROE ÷(株価 ÷ 簿価)は当サイト計算 · 修正ROIは会社計画値。 Definitions: ROI = ROE ÷ (price ÷ book) at 5,962 yen; adjusted ROI uses the FY2026 plan (company KPI).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q4국내 손보사와 비교하면?How does it compare with the Korean P&C insurers?韓国の損保会社と比べると?
답: 같은 IFRS 17 인데 이익 구조가 반대. 영업이익 중 투자 몫 삼성화재 44% · 현대해상 51% · DB손보 52% · 도쿄해상 2%. 국채 대비로는 한국이 쌉니다 — P/B 삼성화재 0.94배 · 현대해상 산출 불가(무배당) · DB손보 0.78배 · 도쿄해상 1.73배, 이익수익률 삼성화재 9.5% · 현대해상 산출 불가 · DB손보 21.0% · 도쿄해상 3.8%. 한국 이익잉여금의 47.5%~65.5%가 법정적립금에 묶여 배당을 막고(현대해상 무배당), 도쿄해상은 IFRS 순이익의 118%를 배당·자사주로 돌려줍니다.
Answer: same IFRS 17, opposite profit structures. Investment share of operating profit Samsung F&M 44% · Hyundai M&F 51% · DB Insurance 52% · Tokio Marine 2%. Against government bonds Korea is cheaper — P/B Samsung F&M 0.94x · Hyundai M&F not derivable (no dividend) · DB Insurance 0.78x · Tokio Marine 1.73x, earnings yield Samsung F&M 9.5% · Hyundai M&F not derivable · DB Insurance 21.0% · Tokio Marine 3.8%. 47.5%–65.5% of Korean retained earnings is tied up in statutory reserves, blocking dividends (Hyundai M&F paid none), while Tokio Marine returns 118% of IFRS net income through dividends and buybacks.
答え:同じIFRS 17なのに利益構造が逆。営業利益に占める投資の割合 Samsung F&M 44% · Hyundai M&F 51% · DB Insurance 52% · Tokio Marine 2%。国債対比では韓国が割安 — PBR Samsung F&M 0.94倍 · Hyundai M&F 算出不可(無配) · DB Insurance 0.78倍 · Tokio Marine 1.73倍、益回り Samsung F&M 9.5% · Hyundai M&F 算出不可 · DB Insurance 21.0% · Tokio Marine 3.8%。韓国の利益剰余金の47.5%〜65.5%が法定積立金に拘束されて配当を妨げ(Hyundai M&Fは無配)、Tokio MarineはIFRS純利益の118%を配当・自己株式取得で還元している。
⚠ 규율: 자세한 지표 15개는 위 '4사 비교' 절의 점수판. 자본비율(K-ICS vs ESR)은 체계가 달라 직접 비교 불가, 주가는 역산값(기준일 3개월 차).
⚠ Discipline: The 15 detailed metrics are in the scorecard of the 'Four-company comparison' section above. Capital ratios (K-ICS vs ESR) are on different regimes and cannot be compared directly; prices are backed-out values (reference dates three months apart).
⚠ 規律:詳細な指標15個は上の「4社比較」の節のスコアカード。資本比率(K-ICS vs ESR)は制度が異なり直接比較できない。株価は逆算値(基準日に3カ月の差)。
Limitations: 한국 = 투자손익 ÷ (보험손익 + 투자손익) · 도쿄해상 = 금융손익 ÷ (서비스손익 + 금융손익) — 정의가 다르다. Definitions: Korea: investment result ÷ (insurance + investment result); Tokio Marine: finance result ÷ (service + finance result).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Korea = investment result ÷ (insurance result + investment result) · Tokio Marine = finance result ÷ (service result + finance result) — the definitions differ. Definitions: Korea: investment result ÷ (insurance + investment result); Tokio Marine: finance result ÷ (service + finance result).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 韓国 = 投資損益 ÷(保険損益 + 投資損益)· Tokio Marine = 金融損益 ÷(サービス損益 + 金融損益)— 定義が異なる。 Definitions: Korea: investment result ÷ (insurance + investment result); Tokio Marine: finance result ÷ (service + finance result).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q5자본 대비 저평가라서, 적은 비용(자사주 매입)으로 사내 돈을 굴리는 게 기대수익이 더 크다고 보는 건가?Is it undervalued relative to equity, so that putting the company's money into cheap buybacks promises a higher expected return?資本に比べて割安なので、少ないコスト(自己株式取得)で社内の資金を回すほうが期待リターンが大きいと見ているのか?
답: '저평가'는 숫자로 확인되지 않지만, '더 큰 기대수익'은 교환 산식으로는 맞습니다. P/B 1.73배(IFRS)로 장부보다 비쌉니다. 그러나 정책주식은 시가 대비 배당 1.70%, 자기 주식은 3월말 주가 대비 이익수익률 IFRS 3.82% · 계획 수정 기준 6.91% · 일본기준 7.05%. 회사 원문(처분 목적): 「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」.
Answer: 'undervalued' is not borne out by the numbers, but 'a higher expected return' holds on the swap arithmetic. At a P/B of 1.73x (IFRS) it trades above book. But policy stocks yield 1.70% in dividends on market value, while own shares yield, on the March-end price, 3.82% on IFRS earnings · 6.91% on the planned adjusted basis · 7.05% on J-GAAP. The company's wording (purpose of disposals): 「FVOCI指定した資本性金融商品について、適正な競争を阻害する要因となりうる政策株式の削減や財務健全性の維持・向上および資本効率の向上等を目的として一部を期中に処分しています。」.
⚠ 규율: 현금 배당(정책주식) vs 회계 이익(자기 주식)이라 단위가 다릅니다. 매입 단가는 有報에 없음. 정책주식은 ESR 리스크량도 씁니다 — 회사 원칙(원문): 「修正ROEへの影響を考慮した上で事業投資や株主還元といった資本政策を決定」.
⚠ Discipline: Cash dividends (policy stocks) vs accounting earnings (own shares) — the units differ. The buyback unit price is not in the annual securities report. Policy stocks also use up ESR risk capital — the company's principle: capital policy, such as business investment and shareholder returns, is decided taking into account the impact on adjusted ROE.
Limitations: 세금·거래비용·가격 영향은 따지지 않았다 · 자기 주식 쪽은 역산 주가 기준. Definitions: policy DY = dividends from FVOCI equities ÷ year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Taxes, transaction costs and price impact are not considered · the own-share side uses the backed-out price. Definitions: policy DY = dividends from FVOCI equities ÷ year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 税金・取引コスト・価格への影響は考慮していない · 自己株式側は逆算株価ベース。 Definitions: policy DY = dividends from FVOCI equities ÷ year-end fair value; own = earnings ÷ March-end implied price 7,309 yen.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q6버핏이 노리는 게 JGB 금리 상승인가? (지금 채권 금리가 오르는데)Is Buffett betting on rising JGB yields? (bond yields are rising now)バフェットが狙うのはJGB金利の上昇か?(今、債券金利が上がっているが)
답: 도쿄해상 장부는 'JGB 롱'이 아닙니다 — 금리 상승의 이득은 부채 쪽에서 나왔습니다. JGB 10년물 2.37% (2026-03-31) → 2.84% (2026-11-12), 출자 이후 +48bp. 같은 기간 회사는 일본 국채 등을 7.77조엔 → 5.98조엔 → 4.20조엔 순으로 줄였습니다. 금리가 오른 두 해의 금리 관련 기타포괄손익(채권 평가 + 보험·재보험 부채 할인율) FY2024 0.03조엔 · FY2025 0.17조엔 — 부채 가치가 채권보다 더 줄어 자본이 늘었습니다. 단, 이는 JGB 가 UST 보다 많이 오른 해의 결과 — 모든 금리가 같이 오르면 자본은 줄어듭니다(회사 민감도, Q12).
Answer: Tokio Marine's books are not 'long JGBs' — the gain from higher rates came from the liability side. JGB 10-year 2.37% (2026-03-31) → 2.84% (2026-11-12), +48bp since the investment. Over the same stretch the company cut its Japanese government bonds etc. JPY 7.77trn → JPY 5.98trn → JPY 4.20trn. In the two years when rates rose, rate-related other comprehensive income (bond revaluation + insurance and reinsurance liability discount rates) was FY2024 JPY 0.03trn · FY2025 JPY 0.17trn — liability values fell by more than bond values, so equity rose. But this is the result of years when JGB yields rose more than UST yields — if all rates rise together, equity falls (company sensitivity, Q12).
⚠ 규율: OCI 에는 신용스프레드·환율 효과도 섞여 '금리만'의 효과는 아닙니다. 출자 이후(2026-04~09)의 효과는 2026-09 半期報告書(11월 제출 예정)에서 확인할 수 있습니다. Berkshire 의 동기·엔화 조달 같은 Raw Data 밖 이야기는 확인하지 않았습니다 — 판단은 사용자 몫.
⚠ Discipline: OCI also mixes in credit-spread and FX effects, so it is not a 'rates only' effect. The effect after the investment (2026-04~09) can be checked in the 2026-09 half-year securities report (due in November). Matters outside the Raw Data, such as Berkshire's motives or yen funding, were not checked — the judgement is the reader's.
Limitations: 재무성 국채금리(복리) · 처분 결의일 커브 vs 최신 커브. Definitions: Ministry of Finance JGB curve; x = maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MOF JGB yields (compound) · curve on the allotment resolution date vs the latest curve. Definitions: Ministry of Finance JGB curve; x = maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 財務省の国債金利(複利)· 処分決議日のカーブ vs 最新のカーブ。 Definitions: Ministry of Finance JGB curve; x = maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q7도쿄해상이 가장 잘 되는 매크로 환경은? (짧은 시계열 말고 레짐으로)In which macro environment does Tokio Marine do best? (by regime, not a short time series)Tokio Marineが最も好調なマクロ環境は?(短い時系列ではなくレジームで)
답(관측): 금리 정상화 레짐에서 가장 좋았습니다. 경계 = 미 실질 10년 금리 저점(2021-08-03 -1.19%). 이전 FY2014~2020: 도쿄해상 연 11.7% vs 닛케이225(가격) 연 10.2% (차이 +1.6%p/년). 이후 FY2021~2025: 연 37.6% vs 11.8% (차이 +25.8%p/년) — 그동안 JGB10Y 0.10% → 2.37%, 미 실질 10년 -0.63% → 2.00%, 엔/달러 약세. 차이 상위: FY2023 +45.8%p · FY2021 +45.7%p · FY2024 +37.6%p · FY2014 +20.5%p. 최저: FY2020 -43.1%p(닛케이225 +54.2%, 미 실질 -0.63%). 차이에는 도쿄해상 배당이 들어 있다(닛케이225 는 배당 제외).
Answer (observation): best in the rate-normalisation regime. Boundary = trough of the US real 10-year yield (2021-08-03 -1.19%). Before, FY2014–2020: Tokio Marine 11.7% a year vs Nikkei 225 (price) 10.2% a year (gap +1.6pp/yr). After, FY2021–2025: 37.6% vs 11.8% a year (gap +25.8pp/yr) — meanwhile JGB10Y 0.10% → 2.37%, US real 10-year -0.63% → 2.00%, and a weaker yen against the dollar. Largest gaps: FY2023 +45.8pp · FY2021 +45.7pp · FY2024 +37.6pp · FY2014 +20.5pp. Lowest: FY2020 -43.1pp (Nikkei 225 +54.2%, US real -0.63%). The gap includes Tokio Marine's dividends (the Nikkei 225 excludes dividends).
⚠ 규율: 표본은 회계연도 12개 — 통계 검정이 아니라 관측입니다. 같은 시기에 회사 고유 사건(정책주식 0 계획 2024-05, 자연재해가 컸던 FY2018~19, 자사주 확대)이 겹쳐 매크로만의 효과로 분리되지 않습니다. 연간 수익률은 보고서마다 지수가 정수로 반올림돼 최대 1.3%p 차이(중앙값 사용).
⚠ Discipline: The sample is 12 fiscal years — an observation, not a statistical test. Company-specific events overlap in the same period (the plan to cut policy stocks to zero, 2024-05; heavy natural catastrophes in FY2018–19; larger buybacks), so the macro effect cannot be isolated. Annual returns differ by up to 1.3pp across reports because each report rounds the index to whole numbers (the median is used).
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 도쿄해상 TSR(배당 포함) vs 닛케이225 가격 수익률(배당 제외) — 차이엔 배당이 섞인다 · 레짐 경계(미 실질 10년 금리 저점)는 데이터로 정했고 경계를 바꾸면 숫자가 달라진다 · 표본이 회계연도 몇 개뿐이라 검정이 아니라 관측. Definitions: Tokio Marine rebuilt from the 5-year TSR tables in each annual report (dividends reinvested); Nikkei 225 = price index, dividends excluded; regime boundary = US real-yield trough.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Tokio Marine TSR (incl. dividends) vs Nikkei 225 price return (excl. dividends) — the gap includes dividends · the regime boundary (US real 10-year yield trough) was set from the data, and moving it changes the numbers · only a handful of fiscal years, so this is an observation, not a test. Definitions: Tokio Marine rebuilt from the 5-year TSR tables in each annual report (dividends reinvested); Nikkei 225 = price index, dividends excluded; regime boundary = US real-yield trough.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Tokio MarineのTSR(配当込み)vs 日経225の価格リターン(配当除く)— 差には配当が混じる · レジームの境界(米実質10年金利の底)はデータで決めており、境界を変えると数字が変わる · 標本は会計年度数個のみのため検定ではなく観測。 Definitions: Tokio Marine rebuilt from the 5-year TSR tables in each annual report (dividends reinvested); Nikkei 225 = price index, dividends excluded; regime boundary = US real-yield trough.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q7 지도Q7 mapQ7 マップRegime map — the same fiscal years with rate, real-yield and yen changesRegime map — the same fiscal years with rate, real-yield and yen changesレジーム・マップ — 同じ会計年度の金利・実質利回り・円の変化
도쿄해상이 닛케이225 보다 크게 앞선 해: FY2023, FY2021, FY2024 — 같은 해 미 10년 +72bp · +58bp · +3bp · JGB10Y +36bp · +11bp · +75bp · 엔/달러 +13.9% · +9.8% · -0.9%. 크게 뒤진 해: FY2020(미 실질 10년 -46bp · 닛케이225 +54.2%). Raw Data 속 연결 고리: 금리↑ → 보험부채 할인 효과(OCI +) · 운용 이율↑ / 엔 약세 → 해외 보험(보험수익의 과반)의 엔 환산 / 주가↑ → 정책주식 평가차익 → 매각 → 환원.
Years when Tokio Marine beat the Nikkei 225 by a wide margin: FY2023, FY2021, FY2024 — in the same years US 10-year +72bp · +58bp · +3bp · JGB10Y +36bp · +11bp · +75bp · USD/JPY +13.9% · +9.8% · -0.9%. Year it lagged badly: FY2020 (US real 10-year -46bp · Nikkei 225 +54.2%). Links in the Raw Data: rates↑ → insurance liability discount effect (OCI +) · higher investment yields / weaker yen → yen translation of international insurance (over half of insurance revenue) / share prices↑ → unrealised gains on policy stocks → sales → shareholder returns.
⚠ 규율: 원천: 도쿄해상 有報 '株主総利回り' 표(EDINET) · 닛케이225 = 증권사 HTS 내보내기(가격지수) · JGB 10년 = 재무성 국채금리정보 · UST 10년·실질 10년·엔/달러 = FRED. 회계연도말(3월 마지막 영업일) 값끼리 비교. 레짐 경계는 데이터로 정했지만(실질금리 저점) 경계 선택에 따라 숫자는 달라집니다.
⚠ Discipline: Sources: Tokio Marine's annual-report total shareholder return table (EDINET) · Nikkei 225 = brokerage HTS export (price index) · JGB 10-year = MOF JGB yield information · UST 10-year, real 10-year and USD/JPY = FRED. Fiscal year-end values compared (last business day of March). The regime boundary was set from the data (the real-yield trough), but the numbers change with the choice of boundary.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 회계연도말(3월 마지막 영업일) 값끼리 비교 · 닛케이225 는 가격지수(배당 제외) · 색 진하기는 열 안의 상대 크기. Definitions: navy = positive, red = negative; shade = size within the column; USD/JPY chg > 0 = weaker yen; rows below the line = after the US real-yield trough; Nikkei 225 = price index.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: Fiscal year-end values compared (last business day of March) · the Nikkei 225 is a price index (dividends excluded) · shade = relative size within the column. Definitions: navy = positive, red = negative; shade = size within the column; USD/JPY chg > 0 = weaker yen; rows below the line = after the US real-yield trough; Nikkei 225 = price index.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 会計年度末(3月最終営業日)の値どうしの比較 · 日経225は価格指数(配当除く)· 色の濃さは列内の相対的な大きさ。 Definitions: navy = positive, red = negative; shade = size within the column; USD/JPY chg > 0 = weaker yen; rows below the line = after the US real-yield trough; Nikkei 225 = price index.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q8보험 유보자금(float)과 영업이익을 엔화로 재투자하는 구조인가? (버핏식 구조라면 이해가 된다)Is the structure one of reinvesting the insurance float and operating profit in yen? (That would make sense if it were a Buffett-style structure)保険の留保資金(フロート)と営業利益を円で再投資する構造なのか?(バフェット流の構造なら理解できる)
답: Raw Data 는 '엔화 재투자'가 아니라 '해외 재배치 + 주주환원'을 보여 줍니다. 운용자산 중 해외 비중 FY2017 29% → FY2024 48% (해외 5.91조엔 → 13.26조엔). 국내 국채(손보+생보) 7.71조엔 → 6.85조엔(FY2020 정점 9.39조엔), IFRS 연결 일본 국채 등 7.77조엔 → 4.20조엔. 보험부채(float)는 일본기준 16.42조엔 (FY2018) → 23.18조엔 (FY2024). FY2018~FY2025 누적: 영업현금흐름 9.04조엔 · 배당+자사주 2.68조엔 · 자회사 인수 0.79조엔.
Answer: the Raw Data shows not 'reinvestment in yen' but 'redeployment overseas + shareholder returns'. Overseas share of invested assets FY2017 29% → FY2024 48% (overseas JPY 5.91trn → JPY 13.26trn). Domestic government bonds (P&C + life) JPY 7.71trn → JPY 6.85trn (peak in FY2020 at JPY 9.39trn), IFRS consolidated Japanese government bonds etc. JPY 7.77trn → JPY 4.20trn. Insurance liabilities (float), J-GAAP, JPY 16.42trn (FY2018) → JPY 23.18trn (FY2024). Cumulative FY2018–FY2025: operating cash flow JPY 9.04trn · dividends + buybacks JPY 2.68trn · acquisitions of subsidiaries JPY 0.79trn.
⚠ 규율: Berkshire 제휴 축(원문)의 'M&A 공동투자'는 이 해외 재배치와 같은 방향입니다. 영업현금흐름은 FY2018~24 일본기준·FY2025 IFRS 를 이어 붙인 값(기준이 달라 합계는 근사). 해외 운용자산 증가에는 엔화 약세 환산 효과가 섞여 있습니다.
⚠ Discipline: The 'joint M&A investment' among the pillars of the Berkshire alliance (original) points the same way as this overseas redeployment. Operating cash flow joins J-GAAP for FY2018–24 and IFRS for FY2025 (different bases, so the total is approximate). The rise in overseas invested assets includes the translation effect of a weaker yen.
Limitations: MD&A 운용자산 표(세그먼트 간 제거 전) · 해외 운용자산의 통화 내역은 표에 없다. Definitions: MD&A invested-assets tables, before inter-segment elimination; international = mostly USD assets.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&A invested-assets tables (before inter-segment elimination) · the currency breakdown of overseas invested assets is not in the tables. Definitions: MD&A invested-assets tables, before inter-segment elimination; international = mostly USD assets.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: MD&Aの運用資産の表(セグメント間消去前)· 海外運用資産の通貨内訳は表にない。 Definitions: MD&A invested-assets tables, before inter-segment elimination; international = mostly USD assets.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q9일본 주식이 좋아서 반영된 것뿐 아닌가? 영업이익이 는 게 아니라Isn't it just the strong Japanese stock market showing through, rather than operating profit growing?日本株が好調だったのが反映されただけではないか?営業利益が増えたのではなく
답: 일본기준 이익 증가는 상당 부분 맞습니다 — 하지만 해외 보험은 따로 컸습니다. 경상이익 FY2018 0.42조엔 → FY2024 1.46조엔 (증가 1.04조엔) 중 주식 매각익 0.08조엔 → 0.81조엔 (증가분의 70%), 국내 본업(나머지)은 0.19조엔 → 0.16조엔, 오히려 줄었습니다. 반면 해외 보험 경상이익 0.14조엔 → 0.49조엔 (3.4배) — 회계연도 평균 엔/달러(110.9 → 152.4)로 나눈 달러 환산으로도 2.5배. 주식 매각익이 없는 IFRS 보험서비스손익은 FY2024 0.96조엔 → FY2025 1.15조엔 (+19%).
Answer: for J-GAAP profit growth, largely yes — but international insurance grew on its own. Of ordinary profit FY2018 JPY 0.42trn → FY2024 JPY 1.46trn (up JPY 1.04trn), stock sale gains went JPY 0.08trn → JPY 0.81trn (70% of the increase), and the domestic core (the rest) went JPY 0.19trn → JPY 0.16trn, a decline. International insurance ordinary profit, by contrast, went JPY 0.14trn → JPY 0.49trn (3.4x) — 2.5x even in dollars at fiscal-year average USD/JPY (110.9 → 152.4). The IFRS insurance service result, which contains no stock sale gains, went FY2024 JPY 0.96trn → FY2025 JPY 1.15trn (+19%).
⚠ 규율: 국내 본업(나머지)에는 정책주식 배당 등 이자·배당 수입이 남아 있어 '일본 주식 몫'을 다 걷어낸 값이 아닙니다. 해외는 달러 외 통화(유로·파운드 등)도 섞여 달러 환산은 근사. 주가는 이익만큼 오르지 않았습니다 — 일본기준 PER 22.7배(FY2020) → 14.2배(FY2025). 그 이유는 Raw Data 에 없습니다.
⚠ Discipline: The domestic core (the rest) still contains interest and dividend income such as dividends on policy stocks, so it does not strip out the whole 'Japanese equity' part. International mixes in non-dollar currencies (euro, sterling, etc.), so the dollar conversion is approximate. The share price did not rise as much as profit — J-GAAP P/E 22.7x (FY2020) → 14.2x (FY2025). The reason is not in the Raw Data.
Limitations: 주식 매각익 = 매도 이익 − 손실 · 국내 핵심 = 합계 − 해외 − 주식 매각익(우리 계산) · 일본기준. Definitions: stock gains = AFS stocks sold, gains − losses; domestic core = total − international − stock gains.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Stock sale gains = gains on sale − losses · domestic core = total − international − stock sale gains (our calculation) · J-GAAP. Definitions: stock gains = AFS stocks sold, gains − losses; domestic core = total − international − stock gains.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q10해외 보험 이익이 늘어봤자 몇 % 인데? 매출로는 몇 % 인가?Even if international insurance profit is growing, what share is it? And what share of revenue?海外保険の利益が増えたところで何%なのか?売上では何%か?
답: 매출의 절반, IFRS 이익의 90%가 해외입니다. 일본기준 매출(세그먼트 경상수익) 해외 비중 FY2018 35% → FY2024 48%, 주식 매각익을 뺀 경상이익 중 해외 42% → 75%. IFRS 보험수익 해외 57% · 세전이익 해외 92%(FY2025) — 국내생보 세전 -0.28조엔. 이자·배당 수입도 해외 69%(FY2024, 0.69조엔 / 1.01조엔).
Answer: half of revenue and 90% of IFRS profit are international. International share of J-GAAP revenue (segment ordinary income) FY2018 35% → FY2024 48%, and of ordinary profit excluding stock sale gains 42% → 75%. IFRS insurance revenue international 57% · pre-tax profit international 92% (FY2025) — domestic life pre-tax JPY -0.28trn. Interest and dividend income is also 69% international (FY2024, JPY 0.69trn / JPY 1.01trn).
⚠ 규율: 일본기준과 IFRS 의 매출·이익 정의가 달라 막대끼리 같은 줄로 잇지 않았습니다. 일본기준 매출 비중은 세그먼트 간 거래를 지우기 전 값.
⚠ Discipline: J-GAAP and IFRS define revenue and profit differently, so the bars are not joined into one line. The J-GAAP revenue share is before eliminating inter-segment transactions.
Limitations: 일본기준 세그먼트(매각익 제외)와 IFRS(보험수익·세전이익)는 정의가 다르다. Definitions: J = J-GAAP segment revenue and ordinary profit excl. stock sale gains; IFRS = insurance revenue and pre-tax profit.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: J-GAAP segments (excl. sale gains) and IFRS (insurance revenue, pre-tax profit) are defined differently. Definitions: J = J-GAAP segment revenue and ordinary profit excl. stock sale gains; IFRS = insurance revenue and pre-tax profit.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 日本基準のセグメント(売却益除く)とIFRS(保険収益・税引前利益)は定義が異なる。 Definitions: J = J-GAAP segment revenue and ordinary profit excl. stock sale gains; IFRS = insurance revenue and pre-tax profit.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q11그건 계절성(일시적) 매출·이익 아닌가?Isn't that seasonal (temporary) revenue and profit?それは季節性(一時的)の売上・利益ではないのか?
답: 매출엔 계절성이 없고, 이익은 사건(재해·코로나)에 출렁입니다. 상반기 매출 비중 해외 48%~51%, 국내손보 48%~53% — 매년 반반. 이익 상반기 비중은 해외 -47%~66% · 국내손보 -13%~76%. 해외 경상이익 달러 환산(회계연도 평균 엔/달러): FY17 $0.64bn · FY18 $1.28bn · FY19 $1.15bn · FY20 $0.42bn · FY21 $1.65bn · FY22 $1.18bn · FY23 $3.13bn · FY24 $3.21bn — FY2023 부터 계단식 상승.
Answer: revenue shows no seasonality; profit swings with events (catastrophes, COVID). First-half share of revenue: international 48%~51%, domestic P&C 48%~53% — half and half every year. First-half share of profit: international -47%~66% · domestic P&C -13%~76%. International ordinary profit in dollars (fiscal-year average USD/JPY): FY17 $0.64bn · FY18 $1.28bn · FY19 $1.15bn · FY20 $0.42bn · FY21 $1.65bn · FY22 $1.18bn · FY23 $3.13bn · FY24 $3.21bn — a step up from FY2023.
⚠ 규율: 국내손보 상반기(7~9월)는 태풍철이라 재해가 큰 해(FY2018·19·22) 상반기 이익이 낮습니다. FY2023~24 해외 이익의 계단 상승이 지속될지는 이 Raw Data 로 판단할 수 없습니다(미 금리 상승기의 운용수익·요율 상승기와 겹침).
⚠ Discipline: Domestic P&C's first half (July–September) is typhoon season, so first-half profit is low in heavy-catastrophe years (FY2018, FY2019, FY2022). Whether the FY2023–24 step up in international profit will last cannot be judged from this Raw Data (it overlaps with higher investment income in the US rate-rise period and a period of rising premium rates).
Limitations: 반기 비중 50 = 계절성 없음 · 일본기준 세그먼트(반기·연간 보고서). Definitions: 50 = no seasonality; J-GAAP segments from half-year and annual reports.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: A half-year share of 50 = no seasonality · J-GAAP segments (half-year and annual reports). Definitions: 50 = no seasonality; J-GAAP segments from half-year and annual reports.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 上半期比率50 = 季節性なし · 日本基準のセグメント(半期・年次報告書)。 Definitions: 50 = no seasonality; J-GAAP segments from half-year and annual reports.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q12보유 JGB·UST 평가손(채권 NAV)은 얼마나 되나?How large are the unrealised losses on the JGBs and USTs held (bond NAV)?保有するJGB・USTの評価損(債券のNAV)はどのくらいか?
Answer: large. J-GAAP unrealised gain/loss on bonds at amortised cost (held to maturity + policy-reserve matching) FY2018 JPY 0.91trn → FY2024 JPY -1.31trn (26% of J-GAAP net assets of JPY 5.10trn). Under IFRS (all bonds at fair value), the cumulative bond revaluation loss in equity went JPY -0.99trn → JPY -1.31trn → JPY -1.43trn, and the cumulative gain from insurance liability discount rates JPY 0.23trn → JPY 0.57trn → JPY 0.86trn — net JPY -0.57trn. Company sensitivity (FY2025): a parallel +0.5pp rate shift moves bonds by JPY -0.47trn and insurance liabilities by JPY 0.27trn, equity net JPY -0.20trn.
⚠ 규율: 정정(Q1·Q6 관련): FY24·25 금리 OCI 가 플러스였던 건 JGB 가 UST 보다 크게 오른 해였기 때문 — 모든 금리가 같이 오르면 자본은 줄어듭니다(회사 공시). 2026-03-31 이후 2026-11-10: JGB10Y +38bp · UST10Y +68bp — 실제 영향은 2026-09 半期報告書에서. FY2024 생보는 만기보유 채권을 매도가능으로 바꿨습니다(원문: 「当連結会計年度において、東京海上日動あんしん生命保険株式会社では、個人保険(利差配当・利差配当一時払)資産区分に属する満期保有目的の債券を全額その他有価証券に変更しています(変更時連結貸借対照表計上額2,019,783百万円)。」). IFRS 채권 누적 평가손은 JGB·UST·회사채 합산(나라별 구분 공시 없음).
⚠ Discipline: Correction (re Q1 and Q6): rate-related OCI was positive in FY24·25 because those were years when JGB yields rose more than UST yields — if all rates rise together, equity falls (company disclosure). From 2026-03-31 to 2026-11-10: JGB10Y +38bp · UST10Y +68bp — the actual impact will show in the 2026-09 half-year securities report. In FY2024 the life insurer reclassified its held-to-maturity bonds as available-for-sale (original: 「当連結会計年度において、東京海上日動あんしん生命保険株式会社では、個人保険(利差配当・利差配当一時払)資産区分に属する満期保有目的の債券を全額その他有価証券に変更しています(変更時連結貸借対照表計上額2,019,783百万円)。」). The cumulative IFRS bond revaluation loss combines JGBs, USTs and corporate bonds (no breakdown by country is disclosed).
Limitations: 만기보유 채권 시가 − 장부(유가증권 주석 공시만) · 일본기준 · 재무상태표 밖. Definitions: fair value − carrying amount; disclosed only in the securities note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Held-to-maturity bonds, fair value − carrying amount (disclosed only in the securities note) · J-GAAP · off balance sheet. Definitions: fair value − carrying amount; disclosed only in the securities note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 満期保有債券の時価 − 簿価(有価証券注記の開示のみ)· 日本基準 · 貸借対照表外。 Definitions: fair value − carrying amount; disclosed only in the securities note.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q13JGB 쿠폰은 미미하고, UST 쿠폰은 엔화 환헤지 비용으로 다 날리는 것 아닌가?JGB coupons are tiny — and doesn't the yen hedging cost wipe out the UST coupon?JGBのクーポンはわずかで、USTのクーポンは円の為替ヘッジコストで消えてしまうのではないか?
답: 엔화 법인이 산 UST 에 대해선 맞지만, 그건 작은 부분입니다. 헤지 비용 근사 2026-11-10 기준 2.70%p → 헤지 후 UST10Y 2.28%(JGB10Y 2.75%보다 낮음), 2023~24 년엔 헤지 후 마이너스. 하지만 달러 채권 대부분은 해외 자회사가 달러 부채를 대고 들고 있어 헤지가 필요 없습니다 — 해외 운용자산 13.26조엔 vs 엔화 법인 외국증권 1.70조엔(FY2024). 이자·배당 수입 해외 69%, 국내생보(국채 중심) 이율 1.40%.
Answer: true for USTs bought by the yen-based entities, but that is a small part. Hedge-cost proxy as of 2026-11-10: 2.70pp → UST10Y after hedging 2.28% (below JGB10Y at 2.75%), and negative after hedging in 2023–24. But most dollar bonds are held by overseas subsidiaries against dollar liabilities, so no hedge is needed — overseas invested assets JPY 13.26trn vs foreign securities at the yen-based entities JPY 1.70trn (FY2024). Interest and dividend income 69% international; domestic life (mostly JGBs) income yield 1.40%.
答え:円建ての法人が買ったUSTについてはその通りだが、それは小さな部分である。ヘッジコストの近似値は2026-11-10時点で2.70pt → ヘッジ後のUST10Y 2.28%(JGB10Y 2.75%より低い)、2023〜24年はヘッジ後マイナス。しかしドル債の大半は海外子会社がドル負債の見合いで保有しており、ヘッジは不要 — 海外運用資産13.26兆円 vs 円建て法人の外国証券1.70兆円(FY2024)。利息・配当収入の海外比率69%、国内生保(国債中心)の利回り1.40%。
⚠ 규율: 헤지 비용은 미 3개월물 − JGB 1년물로 근사(실제 통화스왑·선물환 비용과 다름, 회사 공시 없음). 헤지 비율·대상도 Raw Data 에 없습니다.
⚠ Discipline: The hedge cost is approximated as US 3-month − JGB 1-year (different from actual currency-swap and forward costs; not disclosed by the company). The hedge ratio and hedged items are not in the Raw Data either.
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 환헤지 비용은 대용치(미 단기금리 − 일본 단기금리)이지 회사 실제 헤지 비용이 아니다 · 회계연도 말 + 최신. Definitions: proxy, not the company's actual hedge cost; fiscal year-ends plus latest.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: The FX hedge cost is a proxy (US short rate − Japanese short rate), not the company's actual hedge cost · fiscal year-ends plus the latest. Definitions: proxy, not the company's actual hedge cost; fiscal year-ends plus latest.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Limitations: 為替ヘッジコストは代用値(米短期金利 − 日本短期金利)で、会社の実際のヘッジコストではない · 会計年度末 + 最新。 Definitions: proxy, not the company's actual hedge cost; fiscal year-ends plus latest.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q14해상(손보)이라 장기보다 단·중기물(front-belly) 비중이 클 것 같은데? 10년 이상이면 만기보유해야 해서 난감할 텐데As a P&C insurer, wouldn't it hold more short and medium maturities (front to belly) than long ones? Over 10 years it would have to hold to maturity, which would be awkward損保なので長期より短・中期(フロント〜ベリー)の比率が大きそうだが?10年超なら満期保有せざるを得ず厄介だろう
답: 연결 국채는 반대로 10년 초과가 70% (FY2024) — 장기물은 만기보유·생보 대응 묶음에 있습니다. 손보 성격에 가까운 매도가능 국채는 10년 이내 67%, 회사채 10년 이내 87% — 짐작대로 단·중기. 외국증권(매도가능)은 10년 초과 58%. 국채 10년 초과 비중 FY2019 85% → FY2024 70%. '난감함'에 대한 회사의 대응(원문): 만기보유 → 매도가능 변경(FY2024), 「(ALM)を基本とした資産運用に継続的に取り組み、既に引き受けている生命保険契約の長期負債の一部を再保険会社に出再するなど、金利リスクコントロールの多様化および高度化に努めました。」.
Answer: on the contrary, 70% of consolidated government bonds are over 10 years (FY2024) — the long bonds sit in the held-to-maturity and life-matching buckets. AFS government bonds, closer to the P&C business, are 67% within 10 years, and corporate bonds 87% within 10 years — short and medium term, as guessed. Foreign securities (AFS) are 58% over 10 years. Share of government bonds over 10 years FY2019 85% → FY2024 70%. The company's response to the 'awkwardness' (original): reclassification from held-to-maturity to available-for-sale (FY2024), 「(ALM)を基本とした資産運用に継続的に取り組み、既に引き受けている生命保険契約の長期負債の一部を再保険会社に出再するなど、金利リスクコントロールの多様化および高度化に努めました。」.
⚠ 규율: 상환 예정액은 액면·연결 기준이라 사업별(손보·생보·해외) 구분이 없습니다. FY2025 IFRS 有報엔 이 표가 없어 FY2024 가 마지막.
⚠ Discipline: Redemption amounts are at face value on a consolidated basis, with no split by business (P&C, life, international). The FY2025 IFRS annual securities report lacks this table, so FY2024 is the last.
Limitations: 상환 예정표(액면·연결) · 사업별 구분 없음 · IFRS 有報엔 이 표가 없어 FY2024 가 마지막. Definitions: redemption schedule note (consolidated); AFS = available for sale.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Redemption schedule (face value, consolidated) · no split by business · the IFRS annual securities report lacks this table, so FY2024 is the last. Definitions: redemption schedule note (consolidated); AFS = available for sale.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: 償還予定表(額面・連結)· 事業別の区分なし · IFRSの有報にはこの表がなく、FY2024が最後。 Definitions: redemption schedule note (consolidated); AFS = available for sale.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q15보험료 상승률이 인플레이션보다 높나? (허들: JGB10Y 3.1%대 · 닛케이 TR · 인플레이션 · JGB10Y 실질)Are premiums rising faster than inflation? (hurdles: JGB10Y in the 3.1% range · Nikkei TR · inflation · real JGB10Y)保険料の上昇率はインフレより高いか?(ハードル:JGB10Y 3.1%台 · 日経TR · インフレ · JGB10Y実質)
답: 국내손보 보험료(연 2.4%)는 일본 기대 인플레이션(BEI 2.09%)과 비교해 빠르고, JGB10Y(2.84%)·닛케이225 가격(연 9.0%)보다 각각 낮습니다 / 낮습니다. 해외 달러 보험료(연 7.2%)는 미 CPI(연 3.8%)보다 빠릅니다. FY2018→FY2024 연평균 — 국내손보 正味収入保険料 2.4% vs 일본 BEI(10년, 재무성 공표 2026-09-17) 2.09% · 해외 달러 환산 7.2% vs 미 CPI(같은 회계연도 평균) 3.8% · 연결(엔) 6.7%, 해외 엔화 13.0%(엔 약세 포함). 허들: JGB10Y 2.84%(2026-11-12) · 닛케이225(가격, 배당 제외) 연 9.0%(FY2019~2024). JGB10Y 실질(물가연동국채 수익률, 재무성 공표)은 0.84% — 시장 기준으로 플러스입니다. IFRS 국내손보 보험수익 FY2025 +3.6%.
Answer: Domestic P&C premiums (2.4% a year) are growing faster than Japan's expected inflation (BEI 2.09%), and are lower / lower than the JGB10Y (2.84%) and the Nikkei 225 price index (9.0% a year) respectively. International premiums in dollars (7.2% a year) are growing faster than US CPI (3.8% a year). Annual average FY2018→FY2024 — domestic P&C net premiums written 2.4% vs Japan BEI (10-year, MOF-published 2026-09-17) 2.09% · international in dollars 7.2% vs US CPI (same fiscal-year average) 3.8% · consolidated (yen) 6.7%, international in yen 13.0% (incl. yen weakness). Hurdles: JGB10Y 2.84% (2026-11-12) · Nikkei 225 (price, dividends excluded) 9.0% a year (FY2019–2024). The real JGB10Y yield (inflation-indexed JGB yield, MOF-published) is 0.84% — positive on a market basis. IFRS domestic P&C insurance revenue FY2025 +3.6%.
⚠ 규율: 보험료 '증가율'과 국채 '수익률'·주가 '변화율'은 성격이 다른 숫자입니다 — 사용자 허들 틀을 그대로 옮긴 비교. 닛케이225 는 증권사 HTS 의 가격지수라 배당이 빠져 총수익(TR)보다 낮게 나옵니다. 일본 실현 CPI 는 Raw Data 에 없어 실현 기준 실질금리는 계산하지 않았습니다(BEI 는 기대치). 일본은행 물가 전망치도 Raw Data 밖. 국내손보 보험료는 국내손보 MD&A 표(세그먼트 간 제거 전), FY2024 이후는 IFRS 라 이 표가 없습니다.
⚠ Discipline: Premium 'growth', bond 'yields' and equity 'returns' are different kinds of numbers — the comparison carries over the user's hurdle frame as is. The Nikkei 225 here is the brokerage HTS price index, so dividends are missing and it comes out below total return (TR). Japan's realised CPI is not in the Raw Data, so no realised real rate was calculated (BEI is an expectation). The Bank of Japan's inflation forecasts are also outside the Raw Data. Domestic P&C premiums come from the domestic P&C MD&A table (before inter-segment elimination); after FY2024 the accounts are IFRS and this table does not exist.
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Limitations: 보험료 증가율과 금리·주가 수익률은 성격이 다른 숫자 · 닛케이225 는 가격지수(배당 제외) · 일본 실현 CPI 는 Raw Data 에 없어 BEI(기대치)로 · 국내손보 보험료 = MD&A 표(세그먼트 간 제거 전). Definitions: navy/red = Tokio Marine premiums FY2018–FY2024; other bars = hurdles: JGB 10Y and BEI/real latest, Nikkei 225 (price, excl. dividends) and US CPI over the same fiscal years.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Limitations: Premium growth and bond yields or equity returns are different kinds of numbers · the Nikkei 225 is a price index (dividends excluded) · Japan's realised CPI is not in the Raw Data, so BEI (an expectation) is used · domestic P&C premiums = MD&A table (before inter-segment elimination). Definitions: navy/red = Tokio Marine premiums FY2018–FY2024; other bars = hurdles: JGB 10Y and BEI/real latest, Nikkei 225 (price, excl. dividends) and US CPI over the same fiscal years.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates).
Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index).
Source: brokerage HTS export (Nikkei 225).
Limitations: 保険料の伸び率と金利・株価のリターンは性質の異なる数字 · 日経225は価格指数(配当除く)· 日本の実績CPIはRaw DataにないためBEI(期待値)を使う · 国内損保の保険料 = MD&Aの表(セグメント間消去前)。 Definitions: navy/red = Tokio Marine premiums FY2018–FY2024; other bars = hurdles: JGB 10Y and BEI/real latest, Nikkei 225 (price, excl. dividends) and US CPI over the same fiscal years.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Q15 BEIJapan 10-year break-even inflation at each inflation-indexed JGB auctionJapan 10-year break-even inflation at each inflation-indexed JGB auction物価連動国債の入札ごとの日本10年ブレーク・イーブン・インフレ率
입찰 기준 BEI: 2026-08-12 1.94% (실질 0.86% · 같은 잔존 9.6년 명목 2.80%). 재무성 공표 BEI(유통시장, 2026-09-17 현재): 2.089% = 명목 2.925% − 실질 0.836%. 2013-10 이후 입찰 기준 BEI 범위 -0.12~1.94%.
Auction-based BEI: 2026-08-12 1.94% (real 0.86% · nominal 2.80% at the same remaining 9.6 years). MOF-published BEI (secondary market, as of 2026-09-17): 2.089% = nominal 2.925% − real 0.836%. Range of auction-based BEI since 2013-10: -0.12–1.94%.
⚠ 규율: 입찰 실질수익률은 최저가격 기준 단리, 커브는 재무성 국채금리(복리) — 산식 차이 몇 bp. 물가연동국채는 잔액이 작고(재무성 원문 주석: 「物価連動国債は、元本が物価に連動して増減する国債。8月末時点の発行残高は約10.2兆円。」) 원금 보장(플로어)이 붙어 BEI 가 순수한 기대 인플레이션과 다를 수 있습니다. 재무성 공표 BEI 는 그림 PDF 의 최신값만 읽어 2026-10-02 부터 매일 쌓습니다(과거 일별 선은 Raw Data 에 없음). 원문 출처 주석: 일본상호증권 제공 금리 정보로 재무성 계산.
⚠ Discipline: The auction real yield is a simple yield at the lowest accepted price, while the curve is MOF's JGB yields (compound) — a formula gap of a few bp. Inflation-indexed JGBs have a small outstanding amount (MOF note, original: 「物価連動国債は、元本が物価に連動して増減する国債。8月末時点の発行残高は約10.2兆円。」) and a principal floor, so BEI can differ from pure expected inflation. The MOF-published BEI is read only as the latest value in the chart PDF and has been accumulated daily since 2026-10-02 (no past daily line in the Raw Data). Original source note: calculated by the Ministry of Finance from interest-rate information provided by Japan Bond Trading.
Limitations: 입찰 실질수익률(단리)과 커브(복리)는 산식이 달라 몇 bp 어긋난다 · 명목은 같은 잔존으로 직선 보간(우리 계산) · 물가연동채는 잔액이 작고 원금 보장이 붙는다. Definitions: x = auction dates since 2013-10 (about quarterly); nominal interpolated on the MOF curve at the bond's remaining maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Limitations: The auction real yield (simple) and the curve (compound) use different formulas and differ by a few bp · the nominal yield is linearly interpolated to the same remaining maturity (our calculation) · inflation-indexed JGBs have a small outstanding amount and a principal floor. Definitions: x = auction dates since 2013-10 (about quarterly); nominal interpolated on the MOF curve at the bond's remaining maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。
Limitations: 入札の実質利回り(単利)とカーブ(複利)は算式が異なり数bpずれる · 名目は同じ残存期間に直線補間(当サイト計算)· 物価連動国債は残高が小さく元本保証が付く。 Definitions: x = auction dates since 2013-10 (about quarterly); nominal interpolated on the MOF curve at the bond's remaining maturity.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
16
Raw Data 상태Raw Data statusRaw Dataの状態
검증Checks検証Ledger statusLedger statusRaw Dataの状態
삼성화재: 보고서 31건 · 패널 PASS1 OK · 유가증권표 31 · 지급여력 31 · 배당 9년 · 현대해상: 보고서 31건 · 패널 PASS1 OK · 유가증권표 29 · 지급여력 31 · 배당 7년 · DB손보: 보고서 31건 · 패널 PASS1 OK · 유가증권표 31 · 지급여력 30 · 배당 9년 · 도쿄해상: 보고서 25건 · 검증 369건(원문 자체 불일치 0, 빈 값 1).
Samsung F&M: reports 31 · panel PASS1 OK · securities tables 31 · solvency 31 · dividends 9 years · Hyundai M&F: reports 31 · panel PASS1 OK · securities tables 29 · solvency 31 · dividends 7 years · DB Insurance: reports 31 · panel PASS1 OK · securities tables 31 · solvency 30 · dividends 9 years · Tokio Marine: reports 25 · checks 369 (source-internal inconsistencies 0, blank values 1).
Samsung F&M:報告書31件 · パネルPASS1 OK · 有価証券表31 · 支払余力31 · 配当9年 · Hyundai M&F:報告書31件 · パネルPASS1 OK · 有価証券表29 · 支払余力31 · 配当7年 · DB Insurance:報告書31件 · パネルPASS1 OK · 有価証券表31 · 支払余力30 · 配当9年 · Tokio Marine:報告書25件 · 検証369件(原文自体の不一致0、空の値1)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Limitations: Summary of the Raw Data status (not a chart).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
∞
천장 — 이 페이지가 말할 수 없는 것Ceilings — what this page cannot say限界 — このページが言えないこと
도쿄해상 주가는 시세 Raw Data 가 아닙니다. 有報의 EPS×PER 로 3월말 주가를 역산(세 경로 1% 안 일치) — 연말·현재 수익률은 시세를 붙여야 합니다.
도쿄해상 회계기준이 바뀝니다. FY2025 부터 IFRS(비교 FY2024 포함 두 해). FY2025 일본기준 값은 미감사 참고치. 2024-04 부터 1Q·3Q 보고서가 없어 분기 Raw Data 는 FY2023 3Q 에서 끊깁니다.
정책보유 공시는 최대 보유회사(東京海上日動) 기준이고, 수정순이익은 회사 KPI(비GAAP, FY2021 정의 변경, FY2026 부터 IFRS 정의)입니다.
시대가 둘이다. IFRS 4(~2022)와 17(2023~)의 손익 줄은 이어 붙이지 않았다. 시대를 넘는 건 수입보험료(업무보고서)·순이익·배당·운용자산뿐.
배당수익률은 회사 기재값. 기준가 = 배당기준일 전 1주일 평균 종가. 이익수익률은 그걸로 역산한 주가에 EPS — 배당 없는 해는 못 낸다.
주석 다음 단계: 신용등급별·잔존만기별 채권, 관계기업·지분증권(삼성전자 지분 등), 특수관계자 거래, 전 회사 CSM 잔액·상각.
시세 Raw Data 없음. P/B·시총·총주주환원율(자사주 매입 포함)은 시세를 붙여야 한다.
TOPIX 값은 싣지 않는다. JPX 지수 라이선스 원문(홈페이지 게재도 라이선스료 대상일 수 있음)을 확인할 수 없어 외부 불가로 본다 — 有報 TSR 표의 TOPIX 칸도 뺐다. 일본 주가 기준선은 닛케이225(증권사 HTS 내보내기, 가격지수·배당 제외).
Tokio Marine's share price is not from market-price Raw Data. The March-end price is backed out from EPS × PER in the annual securities report (three routes agree within 1%) — year-end or current yields need market prices attached.
Tokio Marine changes accounting standards. IFRS from FY2025 (two years including the FY2024 comparative). FY2025 J-GAAP figures are unaudited reference values. Q1 and Q3 reports stopped from 2024-04, so the quarterly Raw Data ends at FY2023 Q3.
Policy-holding disclosures are for the largest holding company (Tokio Marine & Nichido), and adjusted net income is a company KPI (non-GAAP; definition revised in FY2021; IFRS definition from FY2026).
Two accounting eras. Profit-and-loss lines under IFRS 4 (to 2022) and IFRS 17 (from 2023) are not joined. Only premium income (business reports), net income, dividends and invested assets cross the break.
Dividend yields are as reported by the companies. Reference price = average close over the week before the dividend record date. Earnings yield = EPS over the price backed out from it — not available for years without a dividend.
Notes, next step: bonds by credit rating and residual maturity, associates and equity securities (e.g. the Samsung Electronics stake), related-party transactions, CSM balances and release for every company.
No market-price Raw Data. P/B, market capitalisation and total shareholder yield (incl. buybacks) need market prices attached.
No TOPIX values. The JPX index licence terms could not be confirmed (even posting on a website may carry a licence fee), so TOPIX is treated as not for external use — the TOPIX column of the annual-report TSR table is dropped as well. The Japanese equity benchmark is the Nikkei 225 (brokerage HTS export, price index, dividends excluded).
Tokio Marineの株価は株価のRaw Dataではない。有報のEPS×PERから3月末株価を逆算(3経路が1%以内で一致)— 年末・現在の利回りは株価を付ける必要がある。
Tokio Marineの会計基準が変わる。FY2025からIFRS(比較のFY2024を含む2年)。FY2025の日本基準の値は未監査の参考値。2024年4月から第1・第3四半期報告書がなく、四半期のRaw DataはFY2023第3四半期で途切れる。
Source: DART, Financial Supervisory Service. 출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13 Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis (H.15 Selected Interest Rates; H.10 Foreign Exchange Rates). Source: U.S. Bureau of Labor Statistics via FRED®, Federal Reserve Bank of St. Louis (Consumer Price Index). 出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0) · EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の各社提出書類をもとにAdrenalin Baby作成(編集・加工) 出典:「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 「国債金利情報」(財務省)(https://www.mof.go.jp/jgbs/reference/interest_rate/index.htm)をもとにAdrenalin Baby作成(編集・加工) 出典:「国債の入札結果(過去の入札結果)— 10年物価連動」(財務省)(https://www.mof.go.jp/jgbs/reference/appendix/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 出典:「ブレーク・イーブン・インフレ率(BEI)の推移」(財務省)(https://www.mof.go.jp/jgbs/topics/bond/10year_inflation-indexed/index.htm)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)(2026年11月13日に利用) · 上記をもとにAdrenalin Baby作成(編集・加工) · BEI 原文注:【出所】日本相互証券提供の金利情報を基に財務省にて計算。 Source: brokerage HTS export (Nikkei 225).